INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42001, 17028, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42002, 17029, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42003, 17030, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42004, 27849, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42005, 27850, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42006, 27851, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42007, 27852, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42008, 14350, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42009, 17025, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42010, 17026, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42011, 17027, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42012, 17028, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42013, 17029, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42014, 17030, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42015, 27849, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42016, 27850, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42017, 27851, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42018, 27852, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42019, 20833, 'Aliskiren', 'Diabetes Mellitus', 'The use of aliskiren is contraindicated in patients with diabetes who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), as there is an increased risk of renal impairment, hyperkalemia, and hypotension.', '3', '"Product Information. Tekturna (aliskiren)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42020, 20833, 'Aliskiren', 'Hypotension', 'Symptomatic hypotension may occur after treatment initiation with aliskiren in patients with marked volume depletion, salt depletion, or with combined use of aliskiren and other agents acting on the renin-angiotensin-aldosterone system.  It is recommended to correct the volume or salt depletion before administering aliskiren.  Close monitoring is recommended.', '2', '"Product Information. Tekturna (aliskiren)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42021, 20833, 'Aliskiren', 'Kidney Diseases', 'Renal function should be monitored periodically in patients treated with aliskiren, as changes can occur including acute renal failure.  Patients on aliskiren whose renal function may depend in part of the RAAS (renin-angiotensin-aldosterone system), such as patients with renal artery stenosis, severe heart failure, or postmyocardial infarction may be at higher risk for developing acute renal failure.  Treatment should be discontinued in any patients who develop clinically significant decrease in renal function.  Patients with renal impairment should be observed closely.  The safety and effectiveness of aliskiren have not been established in patients with severe renal impairment (CrCl < 30 mL/min), as these patients were excluded from clinical trials.', '2', '"Product Information. Tekturna (aliskiren)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42022, 3278, 'Dacarbazine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42023, 3278, 'Dacarbazine', 'Liver Diseases', 'The pharmacokinetic disposition of dacarbazine may be altered in patients with hepatic impairment.  Hepatotoxicity, including hepatic vein thrombosis and hepatocellular necrosis, have been reported.  Patients should be instructed to immediately report any sign or symptoms of liver dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with dacarbazine should be administered cautiously in patients with or predisposed to compromised hepatic function.', '3', 'Marsh JC "Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication." Hepatology 9 (1989):  790-2|Feaux de Lacroix W, Runne U, Hauk H, Doepfmer K, Groth W, Wacker D "Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment." Cancer Treat Rep 67 (1983):  779-84|Sutherland CM, Krementz ET "Hepatic toxicity of DTIC." Cancer Treat Rep 65 (1981):  321-2|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42024, 3278, 'Dacarbazine', 'Bone Marrow Failure Disorders', 'Dacarbazine is myelosuppressive, primarily affecting  leukocytes and thrombocytes, although anemia occasionally occurs.  Deaths due to myelosuppression have been reported.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Therapy with dacarbazine should be withheld or extreme caution exercised when administered in patients whose bone marrow reserve may be severely depressed.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42025, 3278, 'Dacarbazine', 'Kidney Diseases', 'Dacarbazine is partially eliminated by the kidney via renal tubular secretion.  Approximately 40% of dacarbazine is eliminated unchanged in the urine.  The half-life of dacarbazine may be increased in patients with renal impairment.  Rare reports of unspecified, severe renal toxicity has been noted.  Therapy with dacarbazine should be administered cautiously to patients with compromised renal function.  Clinical monitoring of renal function is recommended.', '2', '"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42026, 14350, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42027, 17025, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42028, 17026, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42029, 17027, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42030, 17028, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42031, 17029, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42032, 17030, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42033, 27849, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42034, 27850, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42035, 27851, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42036, 27852, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42037, 14350, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '"Product Information. DepoCyt (cytarabine liposomal)." Sigma-Tau Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42038, 17025, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '"Product Information. DepoCyt (cytarabine liposomal)." Sigma-Tau Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42039, 17026, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '"Product Information. DepoCyt (cytarabine liposomal)." Sigma-Tau Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42040, 17027, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '"Product Information. DepoCyt (cytarabine liposomal)." Sigma-Tau Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42041, 17028, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '"Product Information. DepoCyt (cytarabine liposomal)." Sigma-Tau Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42042, 17029, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '"Product Information. DepoCyt (cytarabine liposomal)." Sigma-Tau Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42043, 17030, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '"Product Information. DepoCyt (cytarabine liposomal)." Sigma-Tau Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42044, 27849, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '"Product Information. DepoCyt (cytarabine liposomal)." Sigma-Tau Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42045, 27850, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '"Product Information. DepoCyt (cytarabine liposomal)." Sigma-Tau Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42046, 27851, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '"Product Information. DepoCyt (cytarabine liposomal)." Sigma-Tau Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42047, 27852, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '"Product Information. DepoCyt (cytarabine liposomal)." Sigma-Tau Pharmaceuticals  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42048, 14350, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42049, 17025, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42050, 17026, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42051, 17027, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42052, 17028, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42053, 17029, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42054, 17030, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42055, 27849, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42056, 27850, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42057, 27851, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42058, 27852, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42059, 0, 'Dabrafenib', 'Cardiomyopathies', 'Cardiomyopathy/reduction in left ventricular ejection fraction (LVEF) has been reported with the use of dabrafenib.  Exercise caution when using this drug in patients at risk of conditions that could impair left ventricular function.  It is recommended to assess LVEF by echocardiogram or multigated acquisition (MUGA) scan before initiation of therapy, 1 month after, and then at 2- to 3-month intervals while on treatment.  Withhold therapy for symptomatic cardiomyopathy or asymptomatic LV dysfunction of greater than 20% from baseline that is below institutional lower level of normal.  Resume therapy at the same dose level upon recovery of cardiac function.', '2', '"Product Information. Tafinlar (dabrafenib)." GlaxoSmithKline  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42060, 0, 'Dabrafenib', 'Diabetes Mellitus', 'The use of dabrafenib may cause hyperglycemia in patients with a history of diabetes.  Care should be exercised when using this drug in diabetic patients.  It is recommended to monitor serum glucose levels at the start of therapy and as clinically indicated.  Initiate or optimize anti-hyperglycemic medications as appropriate.', '2', '"Product Information. Tafinlar (dabrafenib)." GlaxoSmithKline  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42061, 0, 'Dabrafenib', 'Fever', 'Serious febrile reactions and fever of any severity complicated by rigors or chills, hypotension, dehydration, and/or renal failure have been observed with the use of dabrafenib.  The incidence and severity of pyrexia are increased when this drug is administered in combination with trametinib.  Patients with serious non-infectious febrile events responded well to dose interruption and/or dose reduction and supportive care.  It is recommended to withhold therapy for fever of 38.5 degrees Celsius (101.3 degrees Fahrenheit) or higher, for any serious febrile reaction, or fever associated with complications; evaluate for infection.  Consider the administration of antipyretics to resolve fever, and as secondary prophylaxis when resuming therapy for patients with prior episode of severe febrile reaction or fever associated with complications.  For instances in which antipyretics are insufficient, consider administering corticosteroids.  Upon resolution of pyrexia, dose reduction and/or permanent therapy discontinuation may be required.', '2', '"Product Information. Tafinlar (dabrafenib)." GlaxoSmithKline  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42062, 0, 'Dabrafenib', 'Glucosephosphate Dehydrogenase Deficiency', 'Dabrafenib contains a sulfonamide moiety.  Care should be exercised when using this drug in patients with glucose-6-phosphate dehydrogenase (G6PD) as it may increase the risk of hemolytic anemia.  It is recommended to monitor patients with G6PD deficiency for signs of hemolytic anemia during therapy.', '2', '"Product Information. Tafinlar (dabrafenib)." GlaxoSmithKline  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42063, 0, 'Dabrafenib', 'Hemorrhage', 'The use of dabrafenib may increase the change of hemorrhagic events.  Use care when using this drug in patients at risk of bleeding.  It is recommended to permanently discontinue treatment for all Grade 4 hemorrhagic events and for any Grade 3 hemorrhagic events that do not improve.  Withhold therapy for Grade 3 hemorrhagic events; if improved, resume at the next lower dose level.', '2', '"Product Information. Tafinlar (dabrafenib)." GlaxoSmithKline  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42064, 0, 'Dabrafenib', 'Toxic Optic Neuropathy', 'The use of dabrafenib may cause uveitis, including iritis and iridocyclitis.  Care should be exercised when using this agent in patients at risk of ocular toxicities.  During therapy, it is recommended to routinely monitor patients for visual signs and symptoms of uveitis, such as a change in vision, photophobia, and eye pain.  Upon examination, if iritis is diagnosed administer ocular therapy, and continue this drug without a dose modification.  For severe uveitis or iridocyclitis, interrupt therapy and treat as clinically indicated and permanently discontinue treatment for persistent Grade 2 or greater uveitis of 6 weeks or more.  No dose modifications are required if treatment effectively controls ocular inflammation.', '2', '"Product Information. Tafinlar (dabrafenib)." GlaxoSmithKline  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42065, 0, 'Dabrafenib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42066, 0, 'Dalbavancin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42067, 0, 'Dalbavancin', 'Liver Diseases', 'Therapy with dalbavancin should be administered cautiously in patients with moderate or severe liver dysfunction (Child-Pugh B or C) as no data are available to determine the appropriate dosing in these patients.  No dosage adjustment is recommended for patients with mild liver dysfunction (Child-Pugh A).', '2', '"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42068, 0, 'Dalbavancin', 'Kidney Diseases', 'The recommended regimen for dalbavancin in patients with CrCl less than 30 mL/min who are not receiving regularly scheduled hemodialysis is 1125 mg as a single dose OR 750 mg once, followed by 375 mg one week later.  No dosage adjustment is necessary for patients with CrCl greater than 30 mL/min or for patients receiving regularly scheduled hemodialysis; dalbavancin may be administered without regard to the timing of hemodialysis.', '2', '"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42069, 963, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, Raymer JM, Romero JC, Wiesner RH, Krom RAF, B "Cyclosporine-induced hypertension after transplantation." Mayo Clin Proc 69 (1994):  1182-93|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42070, 3210, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, Raymer JM, Romero JC, Wiesner RH, Krom RAF, B "Cyclosporine-induced hypertension after transplantation." Mayo Clin Proc 69 (1994):  1182-93|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42071, 14087, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, Raymer JM, Romero JC, Wiesner RH, Krom RAF, B "Cyclosporine-induced hypertension after transplantation." Mayo Clin Proc 69 (1994):  1182-93|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42072, 14422, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, Raymer JM, Romero JC, Wiesner RH, Krom RAF, B "Cyclosporine-induced hypertension after transplantation." Mayo Clin Proc 69 (1994):  1182-93|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42073, 25927, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, Raymer JM, Romero JC, Wiesner RH, Krom RAF, B "Cyclosporine-induced hypertension after transplantation." Mayo Clin Proc 69 (1994):  1182-93|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42074, 26491, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, Raymer JM, Romero JC, Wiesner RH, Krom RAF, B "Cyclosporine-induced hypertension after transplantation." Mayo Clin Proc 69 (1994):  1182-93|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42075, 26492, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, Raymer JM, Romero JC, Wiesner RH, Krom RAF, B "Cyclosporine-induced hypertension after transplantation." Mayo Clin Proc 69 (1994):  1182-93|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42076, 26493, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, Raymer JM, Romero JC, Wiesner RH, Krom RAF, B "Cyclosporine-induced hypertension after transplantation." Mayo Clin Proc 69 (1994):  1182-93|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42077, 26494, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, Raymer JM, Romero JC, Wiesner RH, Krom RAF, B "Cyclosporine-induced hypertension after transplantation." Mayo Clin Proc 69 (1994):  1182-93|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42078, 963, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', 'Harris KP, Jenkins D, Walls J "Nonsteroidal antiinflammatory drugs and cyclosporine: a potentially serious adverse interaction." Transplantation 46 (1988):  598-9|Bertani T, Ferrazzi P, Schieppati A, et al. "Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients." Kidney Int 40 (1991):  243-50|Madhok R, Torley HI, Capell HA "A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis." J Rheumatol 18 (1991):  1485-9|Ballardie FW, Edwards BD, Hows J, et al. "Disturbance in renal haemodynamics and physiology in bone marrow transplant recipients treated with ciclosporin A." Nephron 60 (1992):  17-24|Butkus DE, Herrera GA, Raju SS "Successful renal transplantation after cyclosporine-associated hemolytic-uremic syndrome following bilateral lung transplantation." Transplantation 54 (1992):  159-62|Margolis DJ, Guzzo C, Johnson J, Lazarus GS "Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day." J Am Acad Dermatol 26 (1992):  195-7|Zachariae H, Hansen HE, Kragballe K, Olsen S "Morphologic renal changes during cyclosporine treatment of psoriasis." J Am Acad Dermatol 26 (1992):  415-9|Burack DA, Griffith BP, Thompson ME, Kahl LE "Hyperuricemia and gout among heart transplant recipients receiving cyclosporine." Am J Med 92 (1992):  141-6|Venkataramanan R, Ptachcinski RJ, Burckart GJ, et al. "The clearance of cyclosporine by hemodialysis." J Clin Pharmacol 24 (1984):  528-31|Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|Dische FE, Neuberger J, Keating J, et al. "Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A." Lab Invest 58 (1988):  395-402|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Morales JM, Andres A, Hernandez E, et al. "Fractional excretion of sodium is an early predictor of cyclosporine nephrotoxicity after renal transplantation." Transplant Proc 22 (1990):  1728-9|Bach JF, Feutren G, Noel LH, et al. "Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels." Transplant Proc 22 (1990):  1296-8|Frey FJ "Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients." Kidney Int 39 (1991):  1034-50|Cantarell MC, Capdevila L, Morlans M, Piera L "Uric acid calculus in renal transplant patients treated with cyclosporine." Clin Nephrol 35 (1991):  288|Dijkmans BA, van Rijthoven AW, The HS, et al. "Effect of cyclosporin on serum creatinine in patients with rheumatoid arthritis." Eur J Clin Pharmacol 31 (1987):  541-5|Follath F, Wenk M, Vozeh S, et al. "Intravenous cyclosporine kinetics in renal failure." Clin Pharmacol Ther 34 (1983):  638-43|Boers M, van Rijthoven AW, The HS, et al. "Serum creatinine levels two years later: follow-up of a placebo-controlled trial of cyclosporine in rheumatoid patients." Transplant Proc 20 (1988):  371-5|Ludwin D, Bennett KJ, Grace EM, et al. "Nephrotoxicity in patients with rheumatoid arthritis treated with cyclosporine." Transplant Proc 20 (1988):  367-70|Messana JM, Rocher LL, Ellis CN, et al. "Effects of cyclosporine on renal function in psoriasis patients." J Am Acad Dermatol 23 (1990):  1288-93|Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR "Cyclosporine kinetics in renal transplantation." Clin Pharmacol Ther 38 (1985):  296-300|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Landewe RBM, The HSG, Vanrijthoven AWAM, Rietveld JR, Breedveld FC, Dijkmans BAC "Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis." J Rheumatol 21 (1994):  1631-6|Forre O, Bjerkhoel F, Kjeldsenkragh J, Ostensen H, Astor T, Boe E, Lekven C, Sorensen JU, Karoliussen O, Dehli O, Glennas A, Kv "Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine - results of a 48-week multicenter study comparing low-dose cyclosporine with placebo." Arthritis Rheum 37 (1994):  1506-12|Bensen W, Tugwell P, Roberts RM, Ludwin D, Ross H, Grace E, Gent M "Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies)." J Rheumatol 21 (1994):  2034-8|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Neumayer HH, Budde K, Farber L, Haller P, Kohnen R, Maibucher A, Schuster A, Vollmar J, Waiser J, Luft FC "Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year." Clin Nephrol 45 (1996):  326-31', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42079, 3210, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', 'Harris KP, Jenkins D, Walls J "Nonsteroidal antiinflammatory drugs and cyclosporine: a potentially serious adverse interaction." Transplantation 46 (1988):  598-9|Bertani T, Ferrazzi P, Schieppati A, et al. "Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients." Kidney Int 40 (1991):  243-50|Madhok R, Torley HI, Capell HA "A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis." J Rheumatol 18 (1991):  1485-9|Ballardie FW, Edwards BD, Hows J, et al. "Disturbance in renal haemodynamics and physiology in bone marrow transplant recipients treated with ciclosporin A." Nephron 60 (1992):  17-24|Butkus DE, Herrera GA, Raju SS "Successful renal transplantation after cyclosporine-associated hemolytic-uremic syndrome following bilateral lung transplantation." Transplantation 54 (1992):  159-62|Margolis DJ, Guzzo C, Johnson J, Lazarus GS "Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day." J Am Acad Dermatol 26 (1992):  195-7|Zachariae H, Hansen HE, Kragballe K, Olsen S "Morphologic renal changes during cyclosporine treatment of psoriasis." J Am Acad Dermatol 26 (1992):  415-9|Burack DA, Griffith BP, Thompson ME, Kahl LE "Hyperuricemia and gout among heart transplant recipients receiving cyclosporine." Am J Med 92 (1992):  141-6|Venkataramanan R, Ptachcinski RJ, Burckart GJ, et al. "The clearance of cyclosporine by hemodialysis." J Clin Pharmacol 24 (1984):  528-31|Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|Dische FE, Neuberger J, Keating J, et al. "Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A." Lab Invest 58 (1988):  395-402|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Morales JM, Andres A, Hernandez E, et al. "Fractional excretion of sodium is an early predictor of cyclosporine nephrotoxicity after renal transplantation." Transplant Proc 22 (1990):  1728-9|Bach JF, Feutren G, Noel LH, et al. "Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels." Transplant Proc 22 (1990):  1296-8|Frey FJ "Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients." Kidney Int 39 (1991):  1034-50|Cantarell MC, Capdevila L, Morlans M, Piera L "Uric acid calculus in renal transplant patients treated with cyclosporine." Clin Nephrol 35 (1991):  288|Dijkmans BA, van Rijthoven AW, The HS, et al. "Effect of cyclosporin on serum creatinine in patients with rheumatoid arthritis." Eur J Clin Pharmacol 31 (1987):  541-5|Follath F, Wenk M, Vozeh S, et al. "Intravenous cyclosporine kinetics in renal failure." Clin Pharmacol Ther 34 (1983):  638-43|Boers M, van Rijthoven AW, The HS, et al. "Serum creatinine levels two years later: follow-up of a placebo-controlled trial of cyclosporine in rheumatoid patients." Transplant Proc 20 (1988):  371-5|Ludwin D, Bennett KJ, Grace EM, et al. "Nephrotoxicity in patients with rheumatoid arthritis treated with cyclosporine." Transplant Proc 20 (1988):  367-70|Messana JM, Rocher LL, Ellis CN, et al. "Effects of cyclosporine on renal function in psoriasis patients." J Am Acad Dermatol 23 (1990):  1288-93|Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR "Cyclosporine kinetics in renal transplantation." Clin Pharmacol Ther 38 (1985):  296-300|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Landewe RBM, The HSG, Vanrijthoven AWAM, Rietveld JR, Breedveld FC, Dijkmans BAC "Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis." J Rheumatol 21 (1994):  1631-6|Forre O, Bjerkhoel F, Kjeldsenkragh J, Ostensen H, Astor T, Boe E, Lekven C, Sorensen JU, Karoliussen O, Dehli O, Glennas A, Kv "Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine - results of a 48-week multicenter study comparing low-dose cyclosporine with placebo." Arthritis Rheum 37 (1994):  1506-12|Bensen W, Tugwell P, Roberts RM, Ludwin D, Ross H, Grace E, Gent M "Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies)." J Rheumatol 21 (1994):  2034-8|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Neumayer HH, Budde K, Farber L, Haller P, Kohnen R, Maibucher A, Schuster A, Vollmar J, Waiser J, Luft FC "Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year." Clin Nephrol 45 (1996):  326-31', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42080, 14087, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', 'Harris KP, Jenkins D, Walls J "Nonsteroidal antiinflammatory drugs and cyclosporine: a potentially serious adverse interaction." Transplantation 46 (1988):  598-9|Bertani T, Ferrazzi P, Schieppati A, et al. "Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients." Kidney Int 40 (1991):  243-50|Madhok R, Torley HI, Capell HA "A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis." J Rheumatol 18 (1991):  1485-9|Ballardie FW, Edwards BD, Hows J, et al. "Disturbance in renal haemodynamics and physiology in bone marrow transplant recipients treated with ciclosporin A." Nephron 60 (1992):  17-24|Butkus DE, Herrera GA, Raju SS "Successful renal transplantation after cyclosporine-associated hemolytic-uremic syndrome following bilateral lung transplantation." Transplantation 54 (1992):  159-62|Margolis DJ, Guzzo C, Johnson J, Lazarus GS "Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day." J Am Acad Dermatol 26 (1992):  195-7|Zachariae H, Hansen HE, Kragballe K, Olsen S "Morphologic renal changes during cyclosporine treatment of psoriasis." J Am Acad Dermatol 26 (1992):  415-9|Burack DA, Griffith BP, Thompson ME, Kahl LE "Hyperuricemia and gout among heart transplant recipients receiving cyclosporine." Am J Med 92 (1992):  141-6|Venkataramanan R, Ptachcinski RJ, Burckart GJ, et al. "The clearance of cyclosporine by hemodialysis." J Clin Pharmacol 24 (1984):  528-31|Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|Dische FE, Neuberger J, Keating J, et al. "Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A." Lab Invest 58 (1988):  395-402|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Morales JM, Andres A, Hernandez E, et al. "Fractional excretion of sodium is an early predictor of cyclosporine nephrotoxicity after renal transplantation." Transplant Proc 22 (1990):  1728-9|Bach JF, Feutren G, Noel LH, et al. "Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels." Transplant Proc 22 (1990):  1296-8|Frey FJ "Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients." Kidney Int 39 (1991):  1034-50|Cantarell MC, Capdevila L, Morlans M, Piera L "Uric acid calculus in renal transplant patients treated with cyclosporine." Clin Nephrol 35 (1991):  288|Dijkmans BA, van Rijthoven AW, The HS, et al. "Effect of cyclosporin on serum creatinine in patients with rheumatoid arthritis." Eur J Clin Pharmacol 31 (1987):  541-5|Follath F, Wenk M, Vozeh S, et al. "Intravenous cyclosporine kinetics in renal failure." Clin Pharmacol Ther 34 (1983):  638-43|Boers M, van Rijthoven AW, The HS, et al. "Serum creatinine levels two years later: follow-up of a placebo-controlled trial of cyclosporine in rheumatoid patients." Transplant Proc 20 (1988):  371-5|Ludwin D, Bennett KJ, Grace EM, et al. "Nephrotoxicity in patients with rheumatoid arthritis treated with cyclosporine." Transplant Proc 20 (1988):  367-70|Messana JM, Rocher LL, Ellis CN, et al. "Effects of cyclosporine on renal function in psoriasis patients." J Am Acad Dermatol 23 (1990):  1288-93|Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR "Cyclosporine kinetics in renal transplantation." Clin Pharmacol Ther 38 (1985):  296-300|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Landewe RBM, The HSG, Vanrijthoven AWAM, Rietveld JR, Breedveld FC, Dijkmans BAC "Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis." J Rheumatol 21 (1994):  1631-6|Forre O, Bjerkhoel F, Kjeldsenkragh J, Ostensen H, Astor T, Boe E, Lekven C, Sorensen JU, Karoliussen O, Dehli O, Glennas A, Kv "Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine - results of a 48-week multicenter study comparing low-dose cyclosporine with placebo." Arthritis Rheum 37 (1994):  1506-12|Bensen W, Tugwell P, Roberts RM, Ludwin D, Ross H, Grace E, Gent M "Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies)." J Rheumatol 21 (1994):  2034-8|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Neumayer HH, Budde K, Farber L, Haller P, Kohnen R, Maibucher A, Schuster A, Vollmar J, Waiser J, Luft FC "Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year." Clin Nephrol 45 (1996):  326-31', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42081, 14422, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', 'Harris KP, Jenkins D, Walls J "Nonsteroidal antiinflammatory drugs and cyclosporine: a potentially serious adverse interaction." Transplantation 46 (1988):  598-9|Bertani T, Ferrazzi P, Schieppati A, et al. "Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients." Kidney Int 40 (1991):  243-50|Madhok R, Torley HI, Capell HA "A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis." J Rheumatol 18 (1991):  1485-9|Ballardie FW, Edwards BD, Hows J, et al. "Disturbance in renal haemodynamics and physiology in bone marrow transplant recipients treated with ciclosporin A." Nephron 60 (1992):  17-24|Butkus DE, Herrera GA, Raju SS "Successful renal transplantation after cyclosporine-associated hemolytic-uremic syndrome following bilateral lung transplantation." Transplantation 54 (1992):  159-62|Margolis DJ, Guzzo C, Johnson J, Lazarus GS "Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day." J Am Acad Dermatol 26 (1992):  195-7|Zachariae H, Hansen HE, Kragballe K, Olsen S "Morphologic renal changes during cyclosporine treatment of psoriasis." J Am Acad Dermatol 26 (1992):  415-9|Burack DA, Griffith BP, Thompson ME, Kahl LE "Hyperuricemia and gout among heart transplant recipients receiving cyclosporine." Am J Med 92 (1992):  141-6|Venkataramanan R, Ptachcinski RJ, Burckart GJ, et al. "The clearance of cyclosporine by hemodialysis." J Clin Pharmacol 24 (1984):  528-31|Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|Dische FE, Neuberger J, Keating J, et al. "Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A." Lab Invest 58 (1988):  395-402|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Morales JM, Andres A, Hernandez E, et al. "Fractional excretion of sodium is an early predictor of cyclosporine nephrotoxicity after renal transplantation." Transplant Proc 22 (1990):  1728-9|Bach JF, Feutren G, Noel LH, et al. "Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels." Transplant Proc 22 (1990):  1296-8|Frey FJ "Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients." Kidney Int 39 (1991):  1034-50|Cantarell MC, Capdevila L, Morlans M, Piera L "Uric acid calculus in renal transplant patients treated with cyclosporine." Clin Nephrol 35 (1991):  288|Dijkmans BA, van Rijthoven AW, The HS, et al. "Effect of cyclosporin on serum creatinine in patients with rheumatoid arthritis." Eur J Clin Pharmacol 31 (1987):  541-5|Follath F, Wenk M, Vozeh S, et al. "Intravenous cyclosporine kinetics in renal failure." Clin Pharmacol Ther 34 (1983):  638-43|Boers M, van Rijthoven AW, The HS, et al. "Serum creatinine levels two years later: follow-up of a placebo-controlled trial of cyclosporine in rheumatoid patients." Transplant Proc 20 (1988):  371-5|Ludwin D, Bennett KJ, Grace EM, et al. "Nephrotoxicity in patients with rheumatoid arthritis treated with cyclosporine." Transplant Proc 20 (1988):  367-70|Messana JM, Rocher LL, Ellis CN, et al. "Effects of cyclosporine on renal function in psoriasis patients." J Am Acad Dermatol 23 (1990):  1288-93|Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR "Cyclosporine kinetics in renal transplantation." Clin Pharmacol Ther 38 (1985):  296-300|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Landewe RBM, The HSG, Vanrijthoven AWAM, Rietveld JR, Breedveld FC, Dijkmans BAC "Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis." J Rheumatol 21 (1994):  1631-6|Forre O, Bjerkhoel F, Kjeldsenkragh J, Ostensen H, Astor T, Boe E, Lekven C, Sorensen JU, Karoliussen O, Dehli O, Glennas A, Kv "Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine - results of a 48-week multicenter study comparing low-dose cyclosporine with placebo." Arthritis Rheum 37 (1994):  1506-12|Bensen W, Tugwell P, Roberts RM, Ludwin D, Ross H, Grace E, Gent M "Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies)." J Rheumatol 21 (1994):  2034-8|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Neumayer HH, Budde K, Farber L, Haller P, Kohnen R, Maibucher A, Schuster A, Vollmar J, Waiser J, Luft FC "Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year." Clin Nephrol 45 (1996):  326-31', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42082, 25927, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', 'Harris KP, Jenkins D, Walls J "Nonsteroidal antiinflammatory drugs and cyclosporine: a potentially serious adverse interaction." Transplantation 46 (1988):  598-9|Bertani T, Ferrazzi P, Schieppati A, et al. "Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients." Kidney Int 40 (1991):  243-50|Madhok R, Torley HI, Capell HA "A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis." J Rheumatol 18 (1991):  1485-9|Ballardie FW, Edwards BD, Hows J, et al. "Disturbance in renal haemodynamics and physiology in bone marrow transplant recipients treated with ciclosporin A." Nephron 60 (1992):  17-24|Butkus DE, Herrera GA, Raju SS "Successful renal transplantation after cyclosporine-associated hemolytic-uremic syndrome following bilateral lung transplantation." Transplantation 54 (1992):  159-62|Margolis DJ, Guzzo C, Johnson J, Lazarus GS "Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day." J Am Acad Dermatol 26 (1992):  195-7|Zachariae H, Hansen HE, Kragballe K, Olsen S "Morphologic renal changes during cyclosporine treatment of psoriasis." J Am Acad Dermatol 26 (1992):  415-9|Burack DA, Griffith BP, Thompson ME, Kahl LE "Hyperuricemia and gout among heart transplant recipients receiving cyclosporine." Am J Med 92 (1992):  141-6|Venkataramanan R, Ptachcinski RJ, Burckart GJ, et al. "The clearance of cyclosporine by hemodialysis." J Clin Pharmacol 24 (1984):  528-31|Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|Dische FE, Neuberger J, Keating J, et al. "Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A." Lab Invest 58 (1988):  395-402|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Morales JM, Andres A, Hernandez E, et al. "Fractional excretion of sodium is an early predictor of cyclosporine nephrotoxicity after renal transplantation." Transplant Proc 22 (1990):  1728-9|Bach JF, Feutren G, Noel LH, et al. "Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels." Transplant Proc 22 (1990):  1296-8|Frey FJ "Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients." Kidney Int 39 (1991):  1034-50|Cantarell MC, Capdevila L, Morlans M, Piera L "Uric acid calculus in renal transplant patients treated with cyclosporine." Clin Nephrol 35 (1991):  288|Dijkmans BA, van Rijthoven AW, The HS, et al. "Effect of cyclosporin on serum creatinine in patients with rheumatoid arthritis." Eur J Clin Pharmacol 31 (1987):  541-5|Follath F, Wenk M, Vozeh S, et al. "Intravenous cyclosporine kinetics in renal failure." Clin Pharmacol Ther 34 (1983):  638-43|Boers M, van Rijthoven AW, The HS, et al. "Serum creatinine levels two years later: follow-up of a placebo-controlled trial of cyclosporine in rheumatoid patients." Transplant Proc 20 (1988):  371-5|Ludwin D, Bennett KJ, Grace EM, et al. "Nephrotoxicity in patients with rheumatoid arthritis treated with cyclosporine." Transplant Proc 20 (1988):  367-70|Messana JM, Rocher LL, Ellis CN, et al. "Effects of cyclosporine on renal function in psoriasis patients." J Am Acad Dermatol 23 (1990):  1288-93|Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR "Cyclosporine kinetics in renal transplantation." Clin Pharmacol Ther 38 (1985):  296-300|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Landewe RBM, The HSG, Vanrijthoven AWAM, Rietveld JR, Breedveld FC, Dijkmans BAC "Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis." J Rheumatol 21 (1994):  1631-6|Forre O, Bjerkhoel F, Kjeldsenkragh J, Ostensen H, Astor T, Boe E, Lekven C, Sorensen JU, Karoliussen O, Dehli O, Glennas A, Kv "Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine - results of a 48-week multicenter study comparing low-dose cyclosporine with placebo." Arthritis Rheum 37 (1994):  1506-12|Bensen W, Tugwell P, Roberts RM, Ludwin D, Ross H, Grace E, Gent M "Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies)." J Rheumatol 21 (1994):  2034-8|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Neumayer HH, Budde K, Farber L, Haller P, Kohnen R, Maibucher A, Schuster A, Vollmar J, Waiser J, Luft FC "Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year." Clin Nephrol 45 (1996):  326-31', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42083, 26491, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', 'Harris KP, Jenkins D, Walls J "Nonsteroidal antiinflammatory drugs and cyclosporine: a potentially serious adverse interaction." Transplantation 46 (1988):  598-9|Bertani T, Ferrazzi P, Schieppati A, et al. "Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients." Kidney Int 40 (1991):  243-50|Madhok R, Torley HI, Capell HA "A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis." J Rheumatol 18 (1991):  1485-9|Ballardie FW, Edwards BD, Hows J, et al. "Disturbance in renal haemodynamics and physiology in bone marrow transplant recipients treated with ciclosporin A." Nephron 60 (1992):  17-24|Butkus DE, Herrera GA, Raju SS "Successful renal transplantation after cyclosporine-associated hemolytic-uremic syndrome following bilateral lung transplantation." Transplantation 54 (1992):  159-62|Margolis DJ, Guzzo C, Johnson J, Lazarus GS "Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day." J Am Acad Dermatol 26 (1992):  195-7|Zachariae H, Hansen HE, Kragballe K, Olsen S "Morphologic renal changes during cyclosporine treatment of psoriasis." J Am Acad Dermatol 26 (1992):  415-9|Burack DA, Griffith BP, Thompson ME, Kahl LE "Hyperuricemia and gout among heart transplant recipients receiving cyclosporine." Am J Med 92 (1992):  141-6|Venkataramanan R, Ptachcinski RJ, Burckart GJ, et al. "The clearance of cyclosporine by hemodialysis." J Clin Pharmacol 24 (1984):  528-31|Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|Dische FE, Neuberger J, Keating J, et al. "Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A." Lab Invest 58 (1988):  395-402|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Morales JM, Andres A, Hernandez E, et al. "Fractional excretion of sodium is an early predictor of cyclosporine nephrotoxicity after renal transplantation." Transplant Proc 22 (1990):  1728-9|Bach JF, Feutren G, Noel LH, et al. "Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels." Transplant Proc 22 (1990):  1296-8|Frey FJ "Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients." Kidney Int 39 (1991):  1034-50|Cantarell MC, Capdevila L, Morlans M, Piera L "Uric acid calculus in renal transplant patients treated with cyclosporine." Clin Nephrol 35 (1991):  288|Dijkmans BA, van Rijthoven AW, The HS, et al. "Effect of cyclosporin on serum creatinine in patients with rheumatoid arthritis." Eur J Clin Pharmacol 31 (1987):  541-5|Follath F, Wenk M, Vozeh S, et al. "Intravenous cyclosporine kinetics in renal failure." Clin Pharmacol Ther 34 (1983):  638-43|Boers M, van Rijthoven AW, The HS, et al. "Serum creatinine levels two years later: follow-up of a placebo-controlled trial of cyclosporine in rheumatoid patients." Transplant Proc 20 (1988):  371-5|Ludwin D, Bennett KJ, Grace EM, et al. "Nephrotoxicity in patients with rheumatoid arthritis treated with cyclosporine." Transplant Proc 20 (1988):  367-70|Messana JM, Rocher LL, Ellis CN, et al. "Effects of cyclosporine on renal function in psoriasis patients." J Am Acad Dermatol 23 (1990):  1288-93|Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR "Cyclosporine kinetics in renal transplantation." Clin Pharmacol Ther 38 (1985):  296-300|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Landewe RBM, The HSG, Vanrijthoven AWAM, Rietveld JR, Breedveld FC, Dijkmans BAC "Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis." J Rheumatol 21 (1994):  1631-6|Forre O, Bjerkhoel F, Kjeldsenkragh J, Ostensen H, Astor T, Boe E, Lekven C, Sorensen JU, Karoliussen O, Dehli O, Glennas A, Kv "Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine - results of a 48-week multicenter study comparing low-dose cyclosporine with placebo." Arthritis Rheum 37 (1994):  1506-12|Bensen W, Tugwell P, Roberts RM, Ludwin D, Ross H, Grace E, Gent M "Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies)." J Rheumatol 21 (1994):  2034-8|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Neumayer HH, Budde K, Farber L, Haller P, Kohnen R, Maibucher A, Schuster A, Vollmar J, Waiser J, Luft FC "Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year." Clin Nephrol 45 (1996):  326-31', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42084, 26492, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', 'Harris KP, Jenkins D, Walls J "Nonsteroidal antiinflammatory drugs and cyclosporine: a potentially serious adverse interaction." Transplantation 46 (1988):  598-9|Bertani T, Ferrazzi P, Schieppati A, et al. "Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients." Kidney Int 40 (1991):  243-50|Madhok R, Torley HI, Capell HA "A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis." J Rheumatol 18 (1991):  1485-9|Ballardie FW, Edwards BD, Hows J, et al. "Disturbance in renal haemodynamics and physiology in bone marrow transplant recipients treated with ciclosporin A." Nephron 60 (1992):  17-24|Butkus DE, Herrera GA, Raju SS "Successful renal transplantation after cyclosporine-associated hemolytic-uremic syndrome following bilateral lung transplantation." Transplantation 54 (1992):  159-62|Margolis DJ, Guzzo C, Johnson J, Lazarus GS "Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day." J Am Acad Dermatol 26 (1992):  195-7|Zachariae H, Hansen HE, Kragballe K, Olsen S "Morphologic renal changes during cyclosporine treatment of psoriasis." J Am Acad Dermatol 26 (1992):  415-9|Burack DA, Griffith BP, Thompson ME, Kahl LE "Hyperuricemia and gout among heart transplant recipients receiving cyclosporine." Am J Med 92 (1992):  141-6|Venkataramanan R, Ptachcinski RJ, Burckart GJ, et al. "The clearance of cyclosporine by hemodialysis." J Clin Pharmacol 24 (1984):  528-31|Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|Dische FE, Neuberger J, Keating J, et al. "Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A." Lab Invest 58 (1988):  395-402|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Morales JM, Andres A, Hernandez E, et al. "Fractional excretion of sodium is an early predictor of cyclosporine nephrotoxicity after renal transplantation." Transplant Proc 22 (1990):  1728-9|Bach JF, Feutren G, Noel LH, et al. "Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels." Transplant Proc 22 (1990):  1296-8|Frey FJ "Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients." Kidney Int 39 (1991):  1034-50|Cantarell MC, Capdevila L, Morlans M, Piera L "Uric acid calculus in renal transplant patients treated with cyclosporine." Clin Nephrol 35 (1991):  288|Dijkmans BA, van Rijthoven AW, The HS, et al. "Effect of cyclosporin on serum creatinine in patients with rheumatoid arthritis." Eur J Clin Pharmacol 31 (1987):  541-5|Follath F, Wenk M, Vozeh S, et al. "Intravenous cyclosporine kinetics in renal failure." Clin Pharmacol Ther 34 (1983):  638-43|Boers M, van Rijthoven AW, The HS, et al. "Serum creatinine levels two years later: follow-up of a placebo-controlled trial of cyclosporine in rheumatoid patients." Transplant Proc 20 (1988):  371-5|Ludwin D, Bennett KJ, Grace EM, et al. "Nephrotoxicity in patients with rheumatoid arthritis treated with cyclosporine." Transplant Proc 20 (1988):  367-70|Messana JM, Rocher LL, Ellis CN, et al. "Effects of cyclosporine on renal function in psoriasis patients." J Am Acad Dermatol 23 (1990):  1288-93|Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR "Cyclosporine kinetics in renal transplantation." Clin Pharmacol Ther 38 (1985):  296-300|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Landewe RBM, The HSG, Vanrijthoven AWAM, Rietveld JR, Breedveld FC, Dijkmans BAC "Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis." J Rheumatol 21 (1994):  1631-6|Forre O, Bjerkhoel F, Kjeldsenkragh J, Ostensen H, Astor T, Boe E, Lekven C, Sorensen JU, Karoliussen O, Dehli O, Glennas A, Kv "Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine - results of a 48-week multicenter study comparing low-dose cyclosporine with placebo." Arthritis Rheum 37 (1994):  1506-12|Bensen W, Tugwell P, Roberts RM, Ludwin D, Ross H, Grace E, Gent M "Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies)." J Rheumatol 21 (1994):  2034-8|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Neumayer HH, Budde K, Farber L, Haller P, Kohnen R, Maibucher A, Schuster A, Vollmar J, Waiser J, Luft FC "Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year." Clin Nephrol 45 (1996):  326-31', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42085, 26493, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', 'Harris KP, Jenkins D, Walls J "Nonsteroidal antiinflammatory drugs and cyclosporine: a potentially serious adverse interaction." Transplantation 46 (1988):  598-9|Bertani T, Ferrazzi P, Schieppati A, et al. "Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients." Kidney Int 40 (1991):  243-50|Madhok R, Torley HI, Capell HA "A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis." J Rheumatol 18 (1991):  1485-9|Ballardie FW, Edwards BD, Hows J, et al. "Disturbance in renal haemodynamics and physiology in bone marrow transplant recipients treated with ciclosporin A." Nephron 60 (1992):  17-24|Butkus DE, Herrera GA, Raju SS "Successful renal transplantation after cyclosporine-associated hemolytic-uremic syndrome following bilateral lung transplantation." Transplantation 54 (1992):  159-62|Margolis DJ, Guzzo C, Johnson J, Lazarus GS "Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day." J Am Acad Dermatol 26 (1992):  195-7|Zachariae H, Hansen HE, Kragballe K, Olsen S "Morphologic renal changes during cyclosporine treatment of psoriasis." J Am Acad Dermatol 26 (1992):  415-9|Burack DA, Griffith BP, Thompson ME, Kahl LE "Hyperuricemia and gout among heart transplant recipients receiving cyclosporine." Am J Med 92 (1992):  141-6|Venkataramanan R, Ptachcinski RJ, Burckart GJ, et al. "The clearance of cyclosporine by hemodialysis." J Clin Pharmacol 24 (1984):  528-31|Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|Dische FE, Neuberger J, Keating J, et al. "Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A." Lab Invest 58 (1988):  395-402|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Morales JM, Andres A, Hernandez E, et al. "Fractional excretion of sodium is an early predictor of cyclosporine nephrotoxicity after renal transplantation." Transplant Proc 22 (1990):  1728-9|Bach JF, Feutren G, Noel LH, et al. "Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels." Transplant Proc 22 (1990):  1296-8|Frey FJ "Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients." Kidney Int 39 (1991):  1034-50|Cantarell MC, Capdevila L, Morlans M, Piera L "Uric acid calculus in renal transplant patients treated with cyclosporine." Clin Nephrol 35 (1991):  288|Dijkmans BA, van Rijthoven AW, The HS, et al. "Effect of cyclosporin on serum creatinine in patients with rheumatoid arthritis." Eur J Clin Pharmacol 31 (1987):  541-5|Follath F, Wenk M, Vozeh S, et al. "Intravenous cyclosporine kinetics in renal failure." Clin Pharmacol Ther 34 (1983):  638-43|Boers M, van Rijthoven AW, The HS, et al. "Serum creatinine levels two years later: follow-up of a placebo-controlled trial of cyclosporine in rheumatoid patients." Transplant Proc 20 (1988):  371-5|Ludwin D, Bennett KJ, Grace EM, et al. "Nephrotoxicity in patients with rheumatoid arthritis treated with cyclosporine." Transplant Proc 20 (1988):  367-70|Messana JM, Rocher LL, Ellis CN, et al. "Effects of cyclosporine on renal function in psoriasis patients." J Am Acad Dermatol 23 (1990):  1288-93|Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR "Cyclosporine kinetics in renal transplantation." Clin Pharmacol Ther 38 (1985):  296-300|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Landewe RBM, The HSG, Vanrijthoven AWAM, Rietveld JR, Breedveld FC, Dijkmans BAC "Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis." J Rheumatol 21 (1994):  1631-6|Forre O, Bjerkhoel F, Kjeldsenkragh J, Ostensen H, Astor T, Boe E, Lekven C, Sorensen JU, Karoliussen O, Dehli O, Glennas A, Kv "Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine - results of a 48-week multicenter study comparing low-dose cyclosporine with placebo." Arthritis Rheum 37 (1994):  1506-12|Bensen W, Tugwell P, Roberts RM, Ludwin D, Ross H, Grace E, Gent M "Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies)." J Rheumatol 21 (1994):  2034-8|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Neumayer HH, Budde K, Farber L, Haller P, Kohnen R, Maibucher A, Schuster A, Vollmar J, Waiser J, Luft FC "Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year." Clin Nephrol 45 (1996):  326-31', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42086, 26494, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', 'Harris KP, Jenkins D, Walls J "Nonsteroidal antiinflammatory drugs and cyclosporine: a potentially serious adverse interaction." Transplantation 46 (1988):  598-9|Bertani T, Ferrazzi P, Schieppati A, et al. "Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients." Kidney Int 40 (1991):  243-50|Madhok R, Torley HI, Capell HA "A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis." J Rheumatol 18 (1991):  1485-9|Ballardie FW, Edwards BD, Hows J, et al. "Disturbance in renal haemodynamics and physiology in bone marrow transplant recipients treated with ciclosporin A." Nephron 60 (1992):  17-24|Butkus DE, Herrera GA, Raju SS "Successful renal transplantation after cyclosporine-associated hemolytic-uremic syndrome following bilateral lung transplantation." Transplantation 54 (1992):  159-62|Margolis DJ, Guzzo C, Johnson J, Lazarus GS "Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day." J Am Acad Dermatol 26 (1992):  195-7|Zachariae H, Hansen HE, Kragballe K, Olsen S "Morphologic renal changes during cyclosporine treatment of psoriasis." J Am Acad Dermatol 26 (1992):  415-9|Burack DA, Griffith BP, Thompson ME, Kahl LE "Hyperuricemia and gout among heart transplant recipients receiving cyclosporine." Am J Med 92 (1992):  141-6|Venkataramanan R, Ptachcinski RJ, Burckart GJ, et al. "The clearance of cyclosporine by hemodialysis." J Clin Pharmacol 24 (1984):  528-31|Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|Dische FE, Neuberger J, Keating J, et al. "Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A." Lab Invest 58 (1988):  395-402|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Morales JM, Andres A, Hernandez E, et al. "Fractional excretion of sodium is an early predictor of cyclosporine nephrotoxicity after renal transplantation." Transplant Proc 22 (1990):  1728-9|Bach JF, Feutren G, Noel LH, et al. "Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels." Transplant Proc 22 (1990):  1296-8|Frey FJ "Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients." Kidney Int 39 (1991):  1034-50|Cantarell MC, Capdevila L, Morlans M, Piera L "Uric acid calculus in renal transplant patients treated with cyclosporine." Clin Nephrol 35 (1991):  288|Dijkmans BA, van Rijthoven AW, The HS, et al. "Effect of cyclosporin on serum creatinine in patients with rheumatoid arthritis." Eur J Clin Pharmacol 31 (1987):  541-5|Follath F, Wenk M, Vozeh S, et al. "Intravenous cyclosporine kinetics in renal failure." Clin Pharmacol Ther 34 (1983):  638-43|Boers M, van Rijthoven AW, The HS, et al. "Serum creatinine levels two years later: follow-up of a placebo-controlled trial of cyclosporine in rheumatoid patients." Transplant Proc 20 (1988):  371-5|Ludwin D, Bennett KJ, Grace EM, et al. "Nephrotoxicity in patients with rheumatoid arthritis treated with cyclosporine." Transplant Proc 20 (1988):  367-70|Messana JM, Rocher LL, Ellis CN, et al. "Effects of cyclosporine on renal function in psoriasis patients." J Am Acad Dermatol 23 (1990):  1288-93|Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR "Cyclosporine kinetics in renal transplantation." Clin Pharmacol Ther 38 (1985):  296-300|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|Landewe RBM, The HSG, Vanrijthoven AWAM, Rietveld JR, Breedveld FC, Dijkmans BAC "Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis." J Rheumatol 21 (1994):  1631-6|Forre O, Bjerkhoel F, Kjeldsenkragh J, Ostensen H, Astor T, Boe E, Lekven C, Sorensen JU, Karoliussen O, Dehli O, Glennas A, Kv "Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine - results of a 48-week multicenter study comparing low-dose cyclosporine with placebo." Arthritis Rheum 37 (1994):  1506-12|Bensen W, Tugwell P, Roberts RM, Ludwin D, Ross H, Grace E, Gent M "Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies)." J Rheumatol 21 (1994):  2034-8|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Neumayer HH, Budde K, Farber L, Haller P, Kohnen R, Maibucher A, Schuster A, Vollmar J, Waiser J, Luft FC "Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year." Clin Nephrol 45 (1996):  326-31', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42087, 963, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', 'Christians U, Kohlhaw K, Budniak J, et al. "Ciclosporin metabolite pattern in blood and urine of liver graft recipients." Eur J Clin Pharmacol 41 (1991):  285-90|Takaya S, Zaghloul I, Iwatsuki S, et al. "Effect of liver dysfunction on cyclosporine pharmacokinetics." Transplant Proc 19 (1987):  1246-7|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Kassianides C, Nussenblatt R, Palestine AG, et al. "Liver injury from cyclosporine A." Dig Dis Sci 35 (1990):  693-7|Sewing K-F, Christians U, Kohlhaw K, et al. "Biologic activity of cyclosporine metabolites." Transplant Proc 22 (1990):  1129-34|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Tredger JM "Using cyclosporine neoral immediately after liver transplantation." Ther Drug Monit 17 (1995):  638-41', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42088, 3210, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', 'Christians U, Kohlhaw K, Budniak J, et al. "Ciclosporin metabolite pattern in blood and urine of liver graft recipients." Eur J Clin Pharmacol 41 (1991):  285-90|Takaya S, Zaghloul I, Iwatsuki S, et al. "Effect of liver dysfunction on cyclosporine pharmacokinetics." Transplant Proc 19 (1987):  1246-7|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Kassianides C, Nussenblatt R, Palestine AG, et al. "Liver injury from cyclosporine A." Dig Dis Sci 35 (1990):  693-7|Sewing K-F, Christians U, Kohlhaw K, et al. "Biologic activity of cyclosporine metabolites." Transplant Proc 22 (1990):  1129-34|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Tredger JM "Using cyclosporine neoral immediately after liver transplantation." Ther Drug Monit 17 (1995):  638-41', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42089, 14087, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', 'Christians U, Kohlhaw K, Budniak J, et al. "Ciclosporin metabolite pattern in blood and urine of liver graft recipients." Eur J Clin Pharmacol 41 (1991):  285-90|Takaya S, Zaghloul I, Iwatsuki S, et al. "Effect of liver dysfunction on cyclosporine pharmacokinetics." Transplant Proc 19 (1987):  1246-7|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Kassianides C, Nussenblatt R, Palestine AG, et al. "Liver injury from cyclosporine A." Dig Dis Sci 35 (1990):  693-7|Sewing K-F, Christians U, Kohlhaw K, et al. "Biologic activity of cyclosporine metabolites." Transplant Proc 22 (1990):  1129-34|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Tredger JM "Using cyclosporine neoral immediately after liver transplantation." Ther Drug Monit 17 (1995):  638-41', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42090, 14422, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', 'Christians U, Kohlhaw K, Budniak J, et al. "Ciclosporin metabolite pattern in blood and urine of liver graft recipients." Eur J Clin Pharmacol 41 (1991):  285-90|Takaya S, Zaghloul I, Iwatsuki S, et al. "Effect of liver dysfunction on cyclosporine pharmacokinetics." Transplant Proc 19 (1987):  1246-7|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Kassianides C, Nussenblatt R, Palestine AG, et al. "Liver injury from cyclosporine A." Dig Dis Sci 35 (1990):  693-7|Sewing K-F, Christians U, Kohlhaw K, et al. "Biologic activity of cyclosporine metabolites." Transplant Proc 22 (1990):  1129-34|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Tredger JM "Using cyclosporine neoral immediately after liver transplantation." Ther Drug Monit 17 (1995):  638-41', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42091, 25927, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', 'Christians U, Kohlhaw K, Budniak J, et al. "Ciclosporin metabolite pattern in blood and urine of liver graft recipients." Eur J Clin Pharmacol 41 (1991):  285-90|Takaya S, Zaghloul I, Iwatsuki S, et al. "Effect of liver dysfunction on cyclosporine pharmacokinetics." Transplant Proc 19 (1987):  1246-7|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Kassianides C, Nussenblatt R, Palestine AG, et al. "Liver injury from cyclosporine A." Dig Dis Sci 35 (1990):  693-7|Sewing K-F, Christians U, Kohlhaw K, et al. "Biologic activity of cyclosporine metabolites." Transplant Proc 22 (1990):  1129-34|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Tredger JM "Using cyclosporine neoral immediately after liver transplantation." Ther Drug Monit 17 (1995):  638-41', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42092, 26491, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', 'Christians U, Kohlhaw K, Budniak J, et al. "Ciclosporin metabolite pattern in blood and urine of liver graft recipients." Eur J Clin Pharmacol 41 (1991):  285-90|Takaya S, Zaghloul I, Iwatsuki S, et al. "Effect of liver dysfunction on cyclosporine pharmacokinetics." Transplant Proc 19 (1987):  1246-7|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Kassianides C, Nussenblatt R, Palestine AG, et al. "Liver injury from cyclosporine A." Dig Dis Sci 35 (1990):  693-7|Sewing K-F, Christians U, Kohlhaw K, et al. "Biologic activity of cyclosporine metabolites." Transplant Proc 22 (1990):  1129-34|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Tredger JM "Using cyclosporine neoral immediately after liver transplantation." Ther Drug Monit 17 (1995):  638-41', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42093, 26492, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', 'Christians U, Kohlhaw K, Budniak J, et al. "Ciclosporin metabolite pattern in blood and urine of liver graft recipients." Eur J Clin Pharmacol 41 (1991):  285-90|Takaya S, Zaghloul I, Iwatsuki S, et al. "Effect of liver dysfunction on cyclosporine pharmacokinetics." Transplant Proc 19 (1987):  1246-7|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Kassianides C, Nussenblatt R, Palestine AG, et al. "Liver injury from cyclosporine A." Dig Dis Sci 35 (1990):  693-7|Sewing K-F, Christians U, Kohlhaw K, et al. "Biologic activity of cyclosporine metabolites." Transplant Proc 22 (1990):  1129-34|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Tredger JM "Using cyclosporine neoral immediately after liver transplantation." Ther Drug Monit 17 (1995):  638-41', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42094, 26493, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', 'Christians U, Kohlhaw K, Budniak J, et al. "Ciclosporin metabolite pattern in blood and urine of liver graft recipients." Eur J Clin Pharmacol 41 (1991):  285-90|Takaya S, Zaghloul I, Iwatsuki S, et al. "Effect of liver dysfunction on cyclosporine pharmacokinetics." Transplant Proc 19 (1987):  1246-7|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Kassianides C, Nussenblatt R, Palestine AG, et al. "Liver injury from cyclosporine A." Dig Dis Sci 35 (1990):  693-7|Sewing K-F, Christians U, Kohlhaw K, et al. "Biologic activity of cyclosporine metabolites." Transplant Proc 22 (1990):  1129-34|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Tredger JM "Using cyclosporine neoral immediately after liver transplantation." Ther Drug Monit 17 (1995):  638-41', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42095, 26494, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', 'Christians U, Kohlhaw K, Budniak J, et al. "Ciclosporin metabolite pattern in blood and urine of liver graft recipients." Eur J Clin Pharmacol 41 (1991):  285-90|Takaya S, Zaghloul I, Iwatsuki S, et al. "Effect of liver dysfunction on cyclosporine pharmacokinetics." Transplant Proc 19 (1987):  1246-7|Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989):  41-8|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|Kassianides C, Nussenblatt R, Palestine AG, et al. "Liver injury from cyclosporine A." Dig Dis Sci 35 (1990):  693-7|Sewing K-F, Christians U, Kohlhaw K, et al. "Biologic activity of cyclosporine metabolites." Transplant Proc 22 (1990):  1129-34|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|Tredger JM "Using cyclosporine neoral immediately after liver transplantation." Ther Drug Monit 17 (1995):  638-41', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42096, 963, 'Cyclosporine', 'Malabsorption Syndromes', 'Patients with malabsorption syndromes may have difficulty achieving therapeutic serum concentrations with the Sandimmune formulations (capsules or solution) of cyclosporine.  An alternative formulation, Neoral (capsule or solution for microemulsion), has increased bioavailability compared to Sandimmune.  Sandimmune and Neoral are not bioequivalent and should not be used interchangeably without physician supervision.', '2', 'Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42097, 3210, 'Cyclosporine', 'Malabsorption Syndromes', 'Patients with malabsorption syndromes may have difficulty achieving therapeutic serum concentrations with the Sandimmune formulations (capsules or solution) of cyclosporine.  An alternative formulation, Neoral (capsule or solution for microemulsion), has increased bioavailability compared to Sandimmune.  Sandimmune and Neoral are not bioequivalent and should not be used interchangeably without physician supervision.', '2', 'Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42098, 14087, 'Cyclosporine', 'Malabsorption Syndromes', 'Patients with malabsorption syndromes may have difficulty achieving therapeutic serum concentrations with the Sandimmune formulations (capsules or solution) of cyclosporine.  An alternative formulation, Neoral (capsule or solution for microemulsion), has increased bioavailability compared to Sandimmune.  Sandimmune and Neoral are not bioequivalent and should not be used interchangeably without physician supervision.', '2', 'Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42099, 14422, 'Cyclosporine', 'Malabsorption Syndromes', 'Patients with malabsorption syndromes may have difficulty achieving therapeutic serum concentrations with the Sandimmune formulations (capsules or solution) of cyclosporine.  An alternative formulation, Neoral (capsule or solution for microemulsion), has increased bioavailability compared to Sandimmune.  Sandimmune and Neoral are not bioequivalent and should not be used interchangeably without physician supervision.', '2', 'Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42100, 25927, 'Cyclosporine', 'Malabsorption Syndromes', 'Patients with malabsorption syndromes may have difficulty achieving therapeutic serum concentrations with the Sandimmune formulations (capsules or solution) of cyclosporine.  An alternative formulation, Neoral (capsule or solution for microemulsion), has increased bioavailability compared to Sandimmune.  Sandimmune and Neoral are not bioequivalent and should not be used interchangeably without physician supervision.', '2', 'Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42101, 26491, 'Cyclosporine', 'Malabsorption Syndromes', 'Patients with malabsorption syndromes may have difficulty achieving therapeutic serum concentrations with the Sandimmune formulations (capsules or solution) of cyclosporine.  An alternative formulation, Neoral (capsule or solution for microemulsion), has increased bioavailability compared to Sandimmune.  Sandimmune and Neoral are not bioequivalent and should not be used interchangeably without physician supervision.', '2', 'Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42102, 26492, 'Cyclosporine', 'Malabsorption Syndromes', 'Patients with malabsorption syndromes may have difficulty achieving therapeutic serum concentrations with the Sandimmune formulations (capsules or solution) of cyclosporine.  An alternative formulation, Neoral (capsule or solution for microemulsion), has increased bioavailability compared to Sandimmune.  Sandimmune and Neoral are not bioequivalent and should not be used interchangeably without physician supervision.', '2', 'Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42103, 26493, 'Cyclosporine', 'Malabsorption Syndromes', 'Patients with malabsorption syndromes may have difficulty achieving therapeutic serum concentrations with the Sandimmune formulations (capsules or solution) of cyclosporine.  An alternative formulation, Neoral (capsule or solution for microemulsion), has increased bioavailability compared to Sandimmune.  Sandimmune and Neoral are not bioequivalent and should not be used interchangeably without physician supervision.', '2', 'Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42104, 26494, 'Cyclosporine', 'Malabsorption Syndromes', 'Patients with malabsorption syndromes may have difficulty achieving therapeutic serum concentrations with the Sandimmune formulations (capsules or solution) of cyclosporine.  An alternative formulation, Neoral (capsule or solution for microemulsion), has increased bioavailability compared to Sandimmune.  Sandimmune and Neoral are not bioequivalent and should not be used interchangeably without physician supervision.', '2', 'Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987):  17-9|de Groen PC, McCallum DK, Moyer TP, Wiesner RH "Pharmacokinetics of cyclosporine in patients with primary biliary cirrhosis." Transplant Proc 20 (1988):  509-11|Vernillet L, Moulin B, Dadoun C, et al. "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988):  529-35|"Product Information. SandIMMUNE (cycloSPORINE)." Apothecon Inc  (2022):|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation|"Product Information. Neoral (cycloSPORINE)." Sandoz Pharmaceuticals Corporation', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42105, 17076, 'Dalfampridine', 'Kidney Diseases', 'Dalfampridine is contraindicated in patients with moderate or severe renal impairment (CrCl<=50 mL/min).  Dalfampridine is eliminated through the kidneys primarily as unchanged drug and its clearance is decreased in patients with renal impairment and is significantly correlated with creatinine clearance.', '3', '"Product Information. Ampyra (dalfampridine)." Acorda Therapeutics  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42106, 25513, 'Dalfampridine', 'Kidney Diseases', 'Dalfampridine is contraindicated in patients with moderate or severe renal impairment (CrCl<=50 mL/min).  Dalfampridine is eliminated through the kidneys primarily as unchanged drug and its clearance is decreased in patients with renal impairment and is significantly correlated with creatinine clearance.', '3', '"Product Information. Ampyra (dalfampridine)." Acorda Therapeutics  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42107, 17076, 'Dalfampridine', 'Seizures', 'Dalfampridine is contraindicated in patients with a history of seizures.  Dalfampridine can cause seizures and it is recommended to permanently discontinue treatment in patients who have a seizure while on treatment.', '3', '"Product Information. Ampyra (dalfampridine)." Acorda Therapeutics  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42108, 25513, 'Dalfampridine', 'Seizures', 'Dalfampridine is contraindicated in patients with a history of seizures.  Dalfampridine can cause seizures and it is recommended to permanently discontinue treatment in patients who have a seizure while on treatment.', '3', '"Product Information. Ampyra (dalfampridine)." Acorda Therapeutics  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42109, 14118, 'Daclatasvir', 'Fibrosis', 'In clinical studies, HCV genotype 3-infected patients with cirrhosis receiving daclatasvir in combination with sofosbuvir for 12 weeks demonstrated reduced sustained virologic response (SVR12) rates.  In addition, in hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfected patients, the use of daclatasvir may cause a reactivation of the HBV.  Some cases have resulted in fulminant hepatitis, hepatic failure, and death.  It is recommended to test all patients for evidence of prior HBV infection before initiating therapy with daclatasvir.  Close monitoring for signs and symptoms of hepatitis flare or HBV reactivation is recommended during HCV treatment with daclatasvir and during after treatment follow-up.  Consider appropriate management for patients with HBV infection as clinically indicated.', '3', '"Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42110, 17050, 'Daclatasvir', 'Fibrosis', 'In clinical studies, HCV genotype 3-infected patients with cirrhosis receiving daclatasvir in combination with sofosbuvir for 12 weeks demonstrated reduced sustained virologic response (SVR12) rates.  In addition, in hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfected patients, the use of daclatasvir may cause a reactivation of the HBV.  Some cases have resulted in fulminant hepatitis, hepatic failure, and death.  It is recommended to test all patients for evidence of prior HBV infection before initiating therapy with daclatasvir.  Close monitoring for signs and symptoms of hepatitis flare or HBV reactivation is recommended during HCV treatment with daclatasvir and during after treatment follow-up.  Consider appropriate management for patients with HBV infection as clinically indicated.', '3', '"Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42111, 17052, 'Daclatasvir', 'Fibrosis', 'In clinical studies, HCV genotype 3-infected patients with cirrhosis receiving daclatasvir in combination with sofosbuvir for 12 weeks demonstrated reduced sustained virologic response (SVR12) rates.  In addition, in hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfected patients, the use of daclatasvir may cause a reactivation of the HBV.  Some cases have resulted in fulminant hepatitis, hepatic failure, and death.  It is recommended to test all patients for evidence of prior HBV infection before initiating therapy with daclatasvir.  Close monitoring for signs and symptoms of hepatitis flare or HBV reactivation is recommended during HCV treatment with daclatasvir and during after treatment follow-up.  Consider appropriate management for patients with HBV infection as clinically indicated.', '3', '"Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42112, 17065, 'Daclatasvir', 'Fibrosis', 'In clinical studies, HCV genotype 3-infected patients with cirrhosis receiving daclatasvir in combination with sofosbuvir for 12 weeks demonstrated reduced sustained virologic response (SVR12) rates.  In addition, in hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfected patients, the use of daclatasvir may cause a reactivation of the HBV.  Some cases have resulted in fulminant hepatitis, hepatic failure, and death.  It is recommended to test all patients for evidence of prior HBV infection before initiating therapy with daclatasvir.  Close monitoring for signs and symptoms of hepatitis flare or HBV reactivation is recommended during HCV treatment with daclatasvir and during after treatment follow-up.  Consider appropriate management for patients with HBV infection as clinically indicated.', '3', '"Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42113, 17069, 'Daclatasvir', 'Fibrosis', 'In clinical studies, HCV genotype 3-infected patients with cirrhosis receiving daclatasvir in combination with sofosbuvir for 12 weeks demonstrated reduced sustained virologic response (SVR12) rates.  In addition, in hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfected patients, the use of daclatasvir may cause a reactivation of the HBV.  Some cases have resulted in fulminant hepatitis, hepatic failure, and death.  It is recommended to test all patients for evidence of prior HBV infection before initiating therapy with daclatasvir.  Close monitoring for signs and symptoms of hepatitis flare or HBV reactivation is recommended during HCV treatment with daclatasvir and during after treatment follow-up.  Consider appropriate management for patients with HBV infection as clinically indicated.', '3', '"Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42114, 21149, 'Daclatasvir', 'Fibrosis', 'In clinical studies, HCV genotype 3-infected patients with cirrhosis receiving daclatasvir in combination with sofosbuvir for 12 weeks demonstrated reduced sustained virologic response (SVR12) rates.  In addition, in hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfected patients, the use of daclatasvir may cause a reactivation of the HBV.  Some cases have resulted in fulminant hepatitis, hepatic failure, and death.  It is recommended to test all patients for evidence of prior HBV infection before initiating therapy with daclatasvir.  Close monitoring for signs and symptoms of hepatitis flare or HBV reactivation is recommended during HCV treatment with daclatasvir and during after treatment follow-up.  Consider appropriate management for patients with HBV infection as clinically indicated.', '3', '"Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42115, 29899, 'Daclatasvir', 'Fibrosis', 'In clinical studies, HCV genotype 3-infected patients with cirrhosis receiving daclatasvir in combination with sofosbuvir for 12 weeks demonstrated reduced sustained virologic response (SVR12) rates.  In addition, in hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfected patients, the use of daclatasvir may cause a reactivation of the HBV.  Some cases have resulted in fulminant hepatitis, hepatic failure, and death.  It is recommended to test all patients for evidence of prior HBV infection before initiating therapy with daclatasvir.  Close monitoring for signs and symptoms of hepatitis flare or HBV reactivation is recommended during HCV treatment with daclatasvir and during after treatment follow-up.  Consider appropriate management for patients with HBV infection as clinically indicated.', '3', '"Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42116, 5099, 'Dacomitinib', 'Kidney Diseases', 'The recommended dose of dacomitinib has not been established for patients with severe renal impairment (CrCl <30 mL/min).  Caution is advised if used in these patients.  No dose adjustment is recommended for patients with mild or moderate renal impairment.', '2', '"Product Information. Vizimpro (dacomitinib)." Pfizer U.S. Pharmaceuticals Group  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42117, 5100, 'Dacomitinib', 'Kidney Diseases', 'The recommended dose of dacomitinib has not been established for patients with severe renal impairment (CrCl <30 mL/min).  Caution is advised if used in these patients.  No dose adjustment is recommended for patients with mild or moderate renal impairment.', '2', '"Product Information. Vizimpro (dacomitinib)." Pfizer U.S. Pharmaceuticals Group  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42118, 5107, 'Dacomitinib', 'Kidney Diseases', 'The recommended dose of dacomitinib has not been established for patients with severe renal impairment (CrCl <30 mL/min).  Caution is advised if used in these patients.  No dose adjustment is recommended for patients with mild or moderate renal impairment.', '2', '"Product Information. Vizimpro (dacomitinib)." Pfizer U.S. Pharmaceuticals Group  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42119, 5099, 'Dacomitinib', 'Liver Failure', 'The recommended dose of dacomitinib has not been established for patients with severe hepatic impairment (total bilirubin > 3 to 10  ULN and any AST).  Caution is advised if used in these patients.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Vizimpro (dacomitinib)." Pfizer U.S. Pharmaceuticals Group  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42120, 5100, 'Dacomitinib', 'Liver Failure', 'The recommended dose of dacomitinib has not been established for patients with severe hepatic impairment (total bilirubin > 3 to 10  ULN and any AST).  Caution is advised if used in these patients.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Vizimpro (dacomitinib)." Pfizer U.S. Pharmaceuticals Group  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42121, 5107, 'Dacomitinib', 'Liver Failure', 'The recommended dose of dacomitinib has not been established for patients with severe hepatic impairment (total bilirubin > 3 to 10  ULN and any AST).  Caution is advised if used in these patients.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.', '2', '"Product Information. Vizimpro (dacomitinib)." Pfizer U.S. Pharmaceuticals Group  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42122, 16837, 'Dactinomycin', 'Infections', 'The use of dactinomycin is contraindicated in patients with known or suspected varicella-zoster or herpes zoster infections.  A severe, generalized, potentially fatal disease has been reported with dactinomycin use during or about the time of such infections.  In addition, dactinomycin can induce myelosuppression, particularly when used with X-ray therapy.  Therefore, dactinomycin therapy should be withheld, or given cautiously, in patients with an infection, depending on the severity.  Close clinical monitoring of hematopoietic function is recommended whenever the drug is administered.  If white blood cell and/or platelet counts are markedly decreased, therapy should be withheld to allow marrow recovery, which often takes up to three weeks.', '3', '"Product Information. Cosmegen (dactinomycin)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42123, 16837, 'Dactinomycin', 'Liver Failure', 'Hepatotoxicity can occur with the use of dactinomycin for injection.  Monitor AST, ALT, alkaline phosphatase, and bilirubin prior to and during dactinomycin therapy.  Caution is advised if used in patients with preexisting liver disease.', '2', '"Product Information. Cosmegen (dactinomycin)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42124, 16837, 'Dactinomycin', 'Bone Marrow Failure Disorders', 'Severe and fatal myelosuppression, which may include neutropenia, thrombocytopenia and anemia, can occur with dactinomycin.  If either the white blood cell or platelet count is markedly decreased, therapy with dactinomycin should be withheld or dose should be reduced to allow recovery.  Therapy with dactinomycin should be administered cautiously in patients with myelosuppression.  Close clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Cosmegen (dactinomycin)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42125, 16837, 'Dactinomycin', 'Kidney Diseases', 'Abnormalities of renal function can occur with dactinomycin for injection.  Monitor creatinine and electrolytes frequently during dactinomycin therapy.  Caution is advised if used in patients with preexisting renal disease.', '2', '"Product Information. Cosmegen (dactinomycin)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42126, 0, 'Danaparoid', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42127, 0, 'Danaparoid', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42128, 0, 'Danaparoid', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'Oates JA, Wood AJJ "Heparin." N Engl J Med 324 (1991):  1565-74|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Walker AM, Jick H "Predictors of bleeding during heparin therapy." JAMA 244 (1980):  1209-12|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Breddin HK "Low molecular weight heparins and bleeding." Semin Thromb Hemost 15 (1989):  401-4|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Hirsh J, Fuster V "Guide to anticoagulant therapy. 1. Heparin." Circulation 89 (1994):  1449-68|Sugiyama T, Itoh M, Ohtawa M, Natsuga T "Study on neutralization of low molecular weight heparin (LHG) by  protamine sulfate and its neutralization characteristics." Thromb Res 68 (1992):  119-29|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42129, 0, 'Danaparoid', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42130, 0, 'Danaparoid', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42131, 0, 'Danaparoid', 'Hypertension', 'Anticoagulants should be used with extreme caution in patients at increased risk for hemorrhage, including those patients with severe hypertension.', '2', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42132, 0, 'Danaparoid', 'Kidney Diseases', 'Anticoagulants should be given with extreme caution to patients with severe kidney dysfunction.  Altered coagulation may increase the risk of bleeding in these patients.  If an anticoagulant is administered, these patients should be monitored closely for signs of bleeding.', '2', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42133, 4962, 'Darunavir', 'Liver Diseases', 'Drug-induced hepatitis has been reported with the use of darunavir/ritonavir.  Patients with underlying liver disease including chronic active hepatitis B or C viral infections have an increased risk for liver function abnormalities.  Therapy with darunavir should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis.  The combination of darunavir/ritonavir is not recommended for use in patients with severe hepatic impairment.', '3', '"Product Information. Prezista (darunavir)." Ortho Biotech Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42134, 4962, 'Darunavir', 'Hemophilia A', 'There have been postmarketing reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis, in types A and B hemophiliac patients treated with protease inhibitors.  However, a causal relationship has not been established.  In some patients, additional Factor VIII was given.  In more than half of the reported cases, protease inhibitor therapy was continued or reintroduced following an interruption.  Hemophiliacs and patients with other coagulation defects should be monitored closely for bleeding during protease inhibitor therapy.', '3', '"Product Information. Invirase (saquinavir)." Roche Laboratories  (2001):|"Product Information. Norvir (ritonavir)." Abbott Pharmaceutical  (2001):|"Product Information. Crixivan (indinavir)." Merck & Co., Inc  (2001):|"Product Information. Viracept (nelfinavir)." Agouron Pharma Inc  (2001):|"Product Information. Agenerase (amprenavir)." Glaxo Wellcome  (2001):|"Product Information. Kaletra (lopinavir-ritonavir)." Abbott Pharmaceutical  (2001):|"Product Information. Fortovase (saquinavir)." Roche Laboratories  (2001):|"Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb  (2003):|"Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline  (2003):|"Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim  (2005):|"Product Information. Prezista (darunavir)." Ortho Biotech Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42135, 4962, 'Darunavir', 'Hyperglycemia', 'New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, glucose intolerance, hyperglycemia, and some cases of diabetic ketoacidosis have been reported during postmarketing surveillance in HIV-infected patients treated with protease inhibitors (PIs).  In some cases, glucose abnormalities/hyperglycemia persisted despite discontinuation of PI therapy.  Frequently, insulin resistance may accompany fat redistribution and serum lipid elevations in what is collectively termed the HIV-associated lipodystrophy syndrome.  Although a causal relationship has not been established, these metabolic disturbances have most often occurred in HIV-infected patients during treatment with potent antiretroviral regimens containing PIs.  Monitoring patients for hyperglycemia, new onset diabetes mellitus, or exacerbation of diabetes mellitus should be considered during PI therapy.  Dosage adjustments in insulin or oral hypoglycemic medications may be necessary in patients with diabetes.', '2', '"Product Information. Invirase (saquinavir)." Roche Laboratories  (2001):|"Product Information. Norvir (ritonavir)." Abbott Pharmaceutical  (2001):|"Product Information. Crixivan (indinavir)." Merck & Co., Inc  (2001):|"Product Information. Viracept (nelfinavir)." Agouron Pharma Inc  (2001):|Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997):  713-4|Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998):  837-8|"Product Information. Agenerase (amprenavir)." Glaxo Wellcome  (2001):|Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999):  162-3|Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999):  114-7|Struble K, Piscitelli SC "Syndromes of abnormal fat redistribution and metabolic complications in HIV-infected patients." Am J Health Syst Pharm 56 (1999):  2343-8|Qaqish RB, Fisher E, Rublein J, Wohl DA "HIV-associated lipodystrophy syndrome." Pharmacotherapy 20 (2000):  13-22|Pujol RM, Domingo P, XavierMatiasGuiu, Francia E, Sanbeat MA, Alomar A, Vazquez G "HIV-1 protease inhibitor-associated partial lipodystrophy: Clinicopathologic review of 14 cases." J Am Acad Dermatol 42 (2000):  193-8|Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000):  2050-6|Carr A "HIV protease inhibitor-related lipodystrophy syndrome." Clin Infect Dis 30 (2000):  s135-42|"Product Information. Kaletra (lopinavir-ritonavir)." Abbott Pharmaceutical  (2001):|"Product Information. Fortovase (saquinavir)." Roche Laboratories  (2001):|Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001):  343-51|Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C "Metabolic effects of indinavir in healthy HIV-seronegative men." Aids 15 (2001):  f11-8|"Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb  (2003):|Brambilla AM, Novati R, Calori G, et al. "Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals." AIDS 17 (2003):  1993-5|"Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline  (2003):|"Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim  (2005):|"Product Information. Prezista (darunavir)." Ortho Biotech Inc  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42136, 1599, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42137, 6775, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42138, 7745, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42139, 7974, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42140, 7975, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42141, 8311, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42142, 9025, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42143, 13384, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42144, 13629, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42145, 13630, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42146, 17105, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42147, 17106, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42148, 17652, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42149, 17653, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42150, 19328, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42151, 19361, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42152, 19362, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42153, 22877, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42154, 23654, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42155, 25693, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42156, 29861, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42157, 30601, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42158, 30602, 'Dapagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42159, 1599, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42160, 6775, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42161, 7745, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42162, 7974, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42163, 7975, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42164, 8311, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42165, 9025, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42166, 13384, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42167, 13629, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42168, 13630, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42169, 17105, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42170, 17106, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42171, 17652, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42172, 17653, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42173, 19328, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42174, 19361, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42175, 19362, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42176, 22877, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42177, 23654, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42178, 25693, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42179, 29861, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42180, 30601, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42181, 30602, 'Dapagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42182, 1599, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42183, 6775, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42184, 7745, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42185, 7974, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42186, 7975, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42187, 8311, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42188, 9025, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42189, 13384, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42190, 13629, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42191, 13630, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42192, 17105, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42193, 17106, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42194, 17652, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42195, 17653, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42196, 19328, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42197, 19361, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42198, 19362, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42199, 22877, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42200, 23654, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42201, 25693, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42202, 29861, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42203, 30601, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42204, 30602, 'Dapagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42205, 1599, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42206, 6775, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42207, 7745, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42208, 7974, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42209, 7975, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42210, 8311, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42211, 9025, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42212, 13384, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42213, 13629, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42214, 13630, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42215, 17105, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42216, 17106, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42217, 17652, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42218, 17653, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42219, 19328, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42220, 19361, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42221, 19362, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42222, 22877, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42223, 23654, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42224, 25693, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42225, 29861, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42226, 30601, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42227, 30602, 'Dapagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42228, 14351, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42229, 14352, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42230, 14354, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42231, 14355, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42232, 14356, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42233, 14357, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42234, 14358, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42235, 14359, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42236, 14360, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42237, 14361, 'Darbepoetin alfa', 'Seizures', 'The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure.  Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations.  It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents.  Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Temple RM, Eadington DW, Swainson CP, Winney R "Seizure related to erythropoietin treatment in patients undergoing dialysis." BMJ 300 (1990):  46|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Beccari M "Seizures in dialysis patients treated with recombinant erythropoietin - review of the literature and guidelines for prevention." Int J Artif Organs 17 (1994):  5-13|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42238, 14351, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42239, 14352, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42240, 14354, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42241, 14355, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42242, 14356, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42243, 14357, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42244, 14358, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42245, 14359, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42246, 14360, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42247, 14361, 'Darbepoetin alfa', 'Diseases requiring hemodialysis', 'The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency.  Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents.  During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.', '3', 'Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. "Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or." Nephron 59 (1991):  399-402|MacDougall IC, Neubert P, Coles GA, Roberts DE, Dharmasena AD, Williams JD "Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Lancet 02/25/89 (1989):  425-7|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Kindler J, Echardt KU, Ehmer B, et al. "Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure." Nephrol Dial Transplant 4 (1989):  345-9|Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW "Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis." Am J Kidney Dis 21 (1993):  635-42|Boran M, Dalva I, Yazicioglu A, Cetin S "Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients." Nephron 63 (1993):  113-4|Lago M, Perezgarcia R, Devinuesa MSG, Anaya F, Valderrabano F "Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients." Nephron 72 (1996):  723-4|Swanepoel C, Jacobs P, Byrne MJ, Rayner B, Cassidy MJD, Meyer J "The effect of recombinant human erythropoietin on haematopoiesis in patients undergoing haemodialysis." S Afr Med J 86 (1996):  952-5|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42248, 14351, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42249, 14352, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42250, 14354, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42251, 14355, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42252, 14356, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42253, 14357, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42254, 14358, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42255, 14359, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42256, 14360, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42257, 14361, 'Darbepoetin alfa', 'Hypertension', 'The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension.  These agents may cause blood pressure to rise.  Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents.  Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment.  Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing.  It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. "Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial." Ann Intern Med 111 (1989):  992-1000|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW "Hypertension following erythropoietin therapy in anemic hemodialysis patients." Am J Hypertens 3 (1990):  947-55|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42258, 14351, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42259, 14352, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42260, 14354, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42261, 14355, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42262, 14356, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42263, 14357, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42264, 14358, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42265, 14359, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42266, 14360, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42267, 14361, 'Darbepoetin alfa', 'Thromboembolism', 'The use of erythropoiesis-stimulating agents may be associated with an increased risk of thrombotic events and mortality.  During clinical trials, an increased risk was observed in:  1) patients with chronic renal failure (CRF) and ischemic heart disease or congestive heart failure targeted to a maintenance hematocrit of 42%, and 2) in patients without CRF undergoing coronary artery bypass surgery.  Although a causal relationship has not been established, therapy with these agents should be administered cautiously in patients with preexisting cardiovascular disease and/or a history of thrombotic events.', '3', 'Bennett WM "Side effects of erythropoietin therapy." Am J Kidney Dis 18 (1991):  84-6|Raine AE "Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy." Lancet 1 (1988):  97-100|Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP "The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients." Clin Nephrol 38 (1992):  277-82|Flaharty KK, Grimm AM, Vlasses PH "Epoetin: human recombinant erythropoietin." Clin Pharm 8 (1989):  769-82|"Product Information. Epogen (epoetin alfa)." Amgen  (2002):|"Product Information. Procrit (epoetin alfa)." Ortho Biotech Inc  (2002):|Lutz B, Tillman K, Santos M, Morvant C, Webb S "Life threatening venous thrombosis associated with high dose epoetin alfa therapy for HIV-related anemia." Int Conf AIDS 9 (1993):  463|Singbartl G "Adverse events of erythropoietin in long-term and in acute short-term treatment." Clin Investig 72 (1994):  s36-43|"Product Information. Aranesp (darbepoetin alfa)." Amgen  (2001):|"Product Information. Mircera (epoetin beta-methoxy polyethylene glycol)." Vifor International Ltd c/o MCT  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42268, 19378, 'Dalteparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42269, 19379, 'Dalteparin', 'Hemophilia A', 'Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42270, 19378, 'Dalteparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42271, 19379, 'Dalteparin', 'Liver Diseases', 'Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42272, 19378, 'Dalteparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'Oates JA, Wood AJJ "Heparin." N Engl J Med 324 (1991):  1565-74|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Walker AM, Jick H "Predictors of bleeding during heparin therapy." JAMA 244 (1980):  1209-12|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Breddin HK "Low molecular weight heparins and bleeding." Semin Thromb Hemost 15 (1989):  401-4|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Hirsh J, Fuster V "Guide to anticoagulant therapy. 1. Heparin." Circulation 89 (1994):  1449-68|Sugiyama T, Itoh M, Ohtawa M, Natsuga T "Study on neutralization of low molecular weight heparin (LHG) by  protamine sulfate and its neutralization characteristics." Thromb Res 68 (1992):  119-29|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42273, 19379, 'Dalteparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'Oates JA, Wood AJJ "Heparin." N Engl J Med 324 (1991):  1565-74|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Walker AM, Jick H "Predictors of bleeding during heparin therapy." JAMA 244 (1980):  1209-12|Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|Breddin HK "Low molecular weight heparins and bleeding." Semin Thromb Hemost 15 (1989):  401-4|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Hirsh J, Fuster V "Guide to anticoagulant therapy. 1. Heparin." Circulation 89 (1994):  1449-68|Sugiyama T, Itoh M, Ohtawa M, Natsuga T "Study on neutralization of low molecular weight heparin (LHG) by  protamine sulfate and its neutralization characteristics." Thromb Res 68 (1992):  119-29|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42274, 19378, 'Dalteparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42275, 19379, 'Dalteparin', 'Diabetic Retinopathy', 'The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy.  Therapy with anticoagulants should be administered with extreme caution in such patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42276, 19378, 'Dalteparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42277, 19379, 'Dalteparin', 'Endocarditis, Subacute Bacterial', 'Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis.  The risk of hemorrhage may be increased in these patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986):  11-8|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Orgaran (danaparoid)." Organon  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42278, 19378, 'Dalteparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', 'Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42279, 19379, 'Dalteparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', 'Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood 78 (1991):  2337-43|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42280, 19378, 'Dalteparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42281, 19379, 'Dalteparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42282, 19378, 'Dalteparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', 'Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42283, 19379, 'Dalteparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', 'Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42284, 19378, 'Dalteparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', 'Bell WR, Royall RM "Heparin-associated thrombocytopenia: a comparison of three heparin preparations." N Engl J Med 303 (1980):  902-7|Cines DB, Kaywin P, Bina M, et al. "Heparin-associated thrombocytopenia." N Engl J Med 303 (1980):  788-95|Kelton JG, Sheridan D, Santos A, et al. "Heparin-induced thrombocytopenia: laboratory studies." Blood 72 (1988):  925-30|Chong BH "Heparin-induced thrombocytopenia." Aust N Z J Med 22 (1992):  145-52|Warkentin TE, Hayward CP, Smith CA, et al. "Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia." J Lab Clin Med 120 (1992):  371-9|Bleasel JF, Rasko JE, Rickard KA, Richards G "Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome." Med J Aust 157 (1992):  192-3|Sandler RM, Seifer DB, Morgan K, Pockros PJ, Wypych J, Weiss LM, Schiffman S "Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG." Am J Clin Pathol 83 (1985):  760-4|Platell CF, Tan EG "Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions." Aust N Z J Surg 56 (1986):  621-3|Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B "Fatal effect of re-exposure to heparin after previous heparin- associated thrombocytopenia and thrombosis ." Lancet 336 (1990):  1077-8|Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37 (1989):  415-8|Lecompte T, Luo SK, Stieltjes N, Lecrubier C, et al. "Thrombocytopenia associated with low-molecular-weight heparin." Lancet 338 (1991):  1217|Eichinger S, Kyrle PA, Brenner B, Wagner B, Kapiotis S, Lechner K, Korninger HC "Thrombocytopenia associated with low-molecular-weight heparin" Lancet 337 (1991):  1425-6|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|Kikta MJ, Keller MP, Humphrey PW, Silver D, Towne JB, Tsapogas M "Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?" Surgery 114 (1993):  705-10|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Balestra B, Quadri P, Biasiutti FD, Furlan M, Lammle B "Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites." Eur J Haematol 53 (1994):  61-3|Tezcan AZ, Tezcan H, Gastineau DA, Armitage JO, Haire WD "Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases." Bone Marrow Transplant 14 (1994):  487-90|Munver R, Schulman IC, Wolf DJ, Rosengart TK "Heparin-induced thrombocytopenia and thrombosis: presentation after cardiopulmonary bypass." Ann Thorac Surg 58 (1994):  1764-6|Kleinschmidt S, Seyfert UT "Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice." Angiology 46 (1995):  37-44|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin." N Engl J Med 332 (1995):  1330-5|Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP "Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia." Am J Hematol 50 (1995):  20-5|Shumate MJ "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1006-7|Hougardy N, Machiels JP, Ravoet C "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Warkentin TE, Hirsh J, Kelton JG "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Ramakrishna R, Manoharan A, Kwan YL, Kyle PW "Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran)." Br J Haematol 91 (1995):  736-8|Force RW "Heparin-induced thrombocytopenia." Am J Health Syst Pharm 52 (1995):  2528|Luzzatto G, Cordiano I, Patrassi G, Fabris F "Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use." Thromb Haemost 75 (1996):  211-2|Peters FPJ, Doevendans PAFM, Erdkamp FLG, Vanderent FWC, Deheer F "Low molecular weight heparin-induced thrombocytopenia and thrombosis." Eur J Haematol 56 (1996):  329-30|Slocum MM, Adams JG, Teel R, Spadone DP, Silver D "Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome." J Vasc Surg 23 (1996):  839-43|Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T "Heparin-induced thrombocytopenia in hemodialysis patients." Am J Kidney Dis 28 (1996):  82-5|Rizzieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996):  157|Chong BH, Magnani HN "Orgaran in heparin-induced thrombocytopenia." Haemostasis 22 (1992):  85-91|Magnani HN "Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost 1993 Dec 20;70(6):1072]." Thromb Haemost 70 (1993):  554-61|Rice P, Dace S, Mcmullin MF, Clements WDB "Heparin induced thrombocytopenia causing life-threatening postoperative haemorrhage." Br J Clin Pract 50 (1996):  404-5|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42285, 19379, 'Dalteparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', 'Bell WR, Royall RM "Heparin-associated thrombocytopenia: a comparison of three heparin preparations." N Engl J Med 303 (1980):  902-7|Cines DB, Kaywin P, Bina M, et al. "Heparin-associated thrombocytopenia." N Engl J Med 303 (1980):  788-95|Kelton JG, Sheridan D, Santos A, et al. "Heparin-induced thrombocytopenia: laboratory studies." Blood 72 (1988):  925-30|Chong BH "Heparin-induced thrombocytopenia." Aust N Z J Med 22 (1992):  145-52|Warkentin TE, Hayward CP, Smith CA, et al. "Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia." J Lab Clin Med 120 (1992):  371-9|Bleasel JF, Rasko JE, Rickard KA, Richards G "Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome." Med J Aust 157 (1992):  192-3|Sandler RM, Seifer DB, Morgan K, Pockros PJ, Wypych J, Weiss LM, Schiffman S "Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG." Am J Clin Pathol 83 (1985):  760-4|Platell CF, Tan EG "Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions." Aust N Z J Surg 56 (1986):  621-3|Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B "Fatal effect of re-exposure to heparin after previous heparin- associated thrombocytopenia and thrombosis ." Lancet 336 (1990):  1077-8|Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37 (1989):  415-8|Lecompte T, Luo SK, Stieltjes N, Lecrubier C, et al. "Thrombocytopenia associated with low-molecular-weight heparin." Lancet 338 (1991):  1217|Eichinger S, Kyrle PA, Brenner B, Wagner B, Kapiotis S, Lechner K, Korninger HC "Thrombocytopenia associated with low-molecular-weight heparin" Lancet 337 (1991):  1425-6|"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|Kikta MJ, Keller MP, Humphrey PW, Silver D, Towne JB, Tsapogas M "Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?" Surgery 114 (1993):  705-10|"Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company  (2001):|Balestra B, Quadri P, Biasiutti FD, Furlan M, Lammle B "Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites." Eur J Haematol 53 (1994):  61-3|Tezcan AZ, Tezcan H, Gastineau DA, Armitage JO, Haire WD "Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases." Bone Marrow Transplant 14 (1994):  487-90|Munver R, Schulman IC, Wolf DJ, Rosengart TK "Heparin-induced thrombocytopenia and thrombosis: presentation after cardiopulmonary bypass." Ann Thorac Surg 58 (1994):  1764-6|Kleinschmidt S, Seyfert UT "Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice." Angiology 46 (1995):  37-44|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin." N Engl J Med 332 (1995):  1330-5|Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP "Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia." Am J Hematol 50 (1995):  20-5|Shumate MJ "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1006-7|Hougardy N, Machiels JP, Ravoet C "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Warkentin TE, Hirsh J, Kelton JG "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995):  1007|Ramakrishna R, Manoharan A, Kwan YL, Kyle PW "Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran)." Br J Haematol 91 (1995):  736-8|Force RW "Heparin-induced thrombocytopenia." Am J Health Syst Pharm 52 (1995):  2528|Luzzatto G, Cordiano I, Patrassi G, Fabris F "Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use." Thromb Haemost 75 (1996):  211-2|Peters FPJ, Doevendans PAFM, Erdkamp FLG, Vanderent FWC, Deheer F "Low molecular weight heparin-induced thrombocytopenia and thrombosis." Eur J Haematol 56 (1996):  329-30|Slocum MM, Adams JG, Teel R, Spadone DP, Silver D "Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome." J Vasc Surg 23 (1996):  839-43|Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T "Heparin-induced thrombocytopenia in hemodialysis patients." Am J Kidney Dis 28 (1996):  82-5|Rizzieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996):  157|Chong BH, Magnani HN "Orgaran in heparin-induced thrombocytopenia." Haemostasis 22 (1992):  85-91|Magnani HN "Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost 1993 Dec 20;70(6):1072]." Thromb Haemost 70 (1993):  554-61|Rice P, Dace S, Mcmullin MF, Clements WDB "Heparin induced thrombocytopenia causing life-threatening postoperative haemorrhage." Br J Clin Pract 50 (1996):  404-5|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42286, 19378, 'Dalteparin', 'Premature Birth', 'Some preparations (i.e., multiple-dose vials) of low molecular weight heparin (LMWH) contain benzyl alcohol as a preservative.  Benzyl alcohol in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions has been associated with fatalities and severe respiratory and metabolic complications in low-birthweight premature infants.  Symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse.  The manufacturers recommend that use of these products be avoided in all neonates whenever possible.  Nevertheless, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  LMWHs are not approved for use in pediatric patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42287, 19379, 'Dalteparin', 'Premature Birth', 'Some preparations (i.e., multiple-dose vials) of low molecular weight heparin (LMWH) contain benzyl alcohol as a preservative.  Benzyl alcohol in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions has been associated with fatalities and severe respiratory and metabolic complications in low-birthweight premature infants.  Symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse.  The manufacturers recommend that use of these products be avoided in all neonates whenever possible.  Nevertheless, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  LMWHs are not approved for use in pediatric patients.', '3', '"Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer  (2002):|"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Normiflo (ardeparin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Innohep (tinzaparin)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42288, 4352, 'Darolutamide', 'Hepatic Insufficiency', 'Patients with moderate hepatic impairment (Child-Pugh Class B) have a higher exposure to darolutamide and reduction of the dose is recommended (see manufacturer package insert for recommended dose).  No dose reduction is needed for patients with mild hepatic impairment.  The effect of severe hepatic impairment (Child-Pugh C) on darolutamide pharmacokinetics is unknown.', '2', '"Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc.  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42289, 4352, 'Darolutamide', 'Kidney Diseases', 'Patients with severe renal impairment (eGFR 15-29 mL/min/1.73 m2) who are not receiving hemodialysis have a higher exposure to darolutamide and reduction of the dose is recommended (see manufacturer package insert for recommended dose).  No dose reduction is needed for patients with mild or moderate renal impairment.  The effect of end stage renal disease (eGFR <15 mL/min/1.73 m2) on darolutamide pharmacokinetics is unknown.', '2', '"Product Information. Adakveo (crizanlizumab)." Novartis Pharmaceuticals  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42290, 3326, 'Dapsone', 'Bone Marrow Failure Disorders', 'The use of dapsone has been associated with development of agranulocytosis, aplastic anemia, and other blood dyscrasias.  Blood dyscrasias are more likely to occur in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Patients should be instructed to report any signs of infection (sore throat, fever, local infection, bleeding, or symptoms of anemia).  Monitoring for hematologic abnormalities is recommended.', '3', 'Laing A "Unusual reaction to intramuscular sulfone in two leprosy patients in malaysia." Int J Lepr 48 (1980):  70|McConkey B "Adverse reactions to dapsone." Lancet 2 (1981):  525|Cook I, Kish M "Haematological safety of long-term malarial prophylaxis with dapsone-pyrimethamine." Med J Aust 143 (1985):  139-41|Potter M, Yates P, Slade R, Kennedy C "Agranulocytosis caused by dapsone therapy for granuloma annulare." J Am Acad Dermatol 20 (1989):  87-8|Hornsten P, Keisu M, Wiholm B "The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988." Arch Dermatol 126 (1990):  919-22|Duhra P, Charles-Holmes R "Linear IgA disease with haemorrhagic pompholyx and dapsone-induced neutropenia." Br J Dermatol 125 (1991):  172-4|Kraus A, Jakez J, Palacios A "Dapsone induced sulfone syndrome and systemic lupus exacerbation." J Rheumatol 19 (1992):  178-9|"Product Information. Dapsone (dapsone)." Jacobus Pharmaceutical Company  (2022):|Cockburn EM, Wood SM, Waller PC, Bleehen SS "Dapsone-induced agranulocytosis: spontaneous reporting data." Br J Dermatol 128 (1993):  702-3|Woodbury GR, Jr  Fried W, Ertle JO, Malkinson FD "Dapsone-associated agranulocytosis and severe anemia in a patient with leukocytoclastic vasculitis." J Am Acad Dermatol 28 (1993):  781-3|Meyerson MA, Cohen PR "Dapsone-induced aplastic anemia in a woman with bullous systemic lupus erythematosus." Mayo Clin Proc 69 (1994):  1159-62|Raizman MB, Fay AM, Weiss JS "Dapsone induced neutropenia in patients treated for ocular cicatricial pemphigoid." Ophthalmology 101 (1994):  1805-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42291, 5227, 'Dapsone', 'Bone Marrow Failure Disorders', 'The use of dapsone has been associated with development of agranulocytosis, aplastic anemia, and other blood dyscrasias.  Blood dyscrasias are more likely to occur in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Patients should be instructed to report any signs of infection (sore throat, fever, local infection, bleeding, or symptoms of anemia).  Monitoring for hematologic abnormalities is recommended.', '3', 'Laing A "Unusual reaction to intramuscular sulfone in two leprosy patients in malaysia." Int J Lepr 48 (1980):  70|McConkey B "Adverse reactions to dapsone." Lancet 2 (1981):  525|Cook I, Kish M "Haematological safety of long-term malarial prophylaxis with dapsone-pyrimethamine." Med J Aust 143 (1985):  139-41|Potter M, Yates P, Slade R, Kennedy C "Agranulocytosis caused by dapsone therapy for granuloma annulare." J Am Acad Dermatol 20 (1989):  87-8|Hornsten P, Keisu M, Wiholm B "The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988." Arch Dermatol 126 (1990):  919-22|Duhra P, Charles-Holmes R "Linear IgA disease with haemorrhagic pompholyx and dapsone-induced neutropenia." Br J Dermatol 125 (1991):  172-4|Kraus A, Jakez J, Palacios A "Dapsone induced sulfone syndrome and systemic lupus exacerbation." J Rheumatol 19 (1992):  178-9|"Product Information. Dapsone (dapsone)." Jacobus Pharmaceutical Company  (2022):|Cockburn EM, Wood SM, Waller PC, Bleehen SS "Dapsone-induced agranulocytosis: spontaneous reporting data." Br J Dermatol 128 (1993):  702-3|Woodbury GR, Jr  Fried W, Ertle JO, Malkinson FD "Dapsone-associated agranulocytosis and severe anemia in a patient with leukocytoclastic vasculitis." J Am Acad Dermatol 28 (1993):  781-3|Meyerson MA, Cohen PR "Dapsone-induced aplastic anemia in a woman with bullous systemic lupus erythematosus." Mayo Clin Proc 69 (1994):  1159-62|Raizman MB, Fay AM, Weiss JS "Dapsone induced neutropenia in patients treated for ocular cicatricial pemphigoid." Ophthalmology 101 (1994):  1805-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42292, 12978, 'Dapsone', 'Bone Marrow Failure Disorders', 'The use of dapsone has been associated with development of agranulocytosis, aplastic anemia, and other blood dyscrasias.  Blood dyscrasias are more likely to occur in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Patients should be instructed to report any signs of infection (sore throat, fever, local infection, bleeding, or symptoms of anemia).  Monitoring for hematologic abnormalities is recommended.', '3', 'Laing A "Unusual reaction to intramuscular sulfone in two leprosy patients in malaysia." Int J Lepr 48 (1980):  70|McConkey B "Adverse reactions to dapsone." Lancet 2 (1981):  525|Cook I, Kish M "Haematological safety of long-term malarial prophylaxis with dapsone-pyrimethamine." Med J Aust 143 (1985):  139-41|Potter M, Yates P, Slade R, Kennedy C "Agranulocytosis caused by dapsone therapy for granuloma annulare." J Am Acad Dermatol 20 (1989):  87-8|Hornsten P, Keisu M, Wiholm B "The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988." Arch Dermatol 126 (1990):  919-22|Duhra P, Charles-Holmes R "Linear IgA disease with haemorrhagic pompholyx and dapsone-induced neutropenia." Br J Dermatol 125 (1991):  172-4|Kraus A, Jakez J, Palacios A "Dapsone induced sulfone syndrome and systemic lupus exacerbation." J Rheumatol 19 (1992):  178-9|"Product Information. Dapsone (dapsone)." Jacobus Pharmaceutical Company  (2022):|Cockburn EM, Wood SM, Waller PC, Bleehen SS "Dapsone-induced agranulocytosis: spontaneous reporting data." Br J Dermatol 128 (1993):  702-3|Woodbury GR, Jr  Fried W, Ertle JO, Malkinson FD "Dapsone-associated agranulocytosis and severe anemia in a patient with leukocytoclastic vasculitis." J Am Acad Dermatol 28 (1993):  781-3|Meyerson MA, Cohen PR "Dapsone-induced aplastic anemia in a woman with bullous systemic lupus erythematosus." Mayo Clin Proc 69 (1994):  1159-62|Raizman MB, Fay AM, Weiss JS "Dapsone induced neutropenia in patients treated for ocular cicatricial pemphigoid." Ophthalmology 101 (1994):  1805-7', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42293, 3326, 'Dapsone', 'Liver Diseases', 'The use of dapsone has been associated with the development of hyperbilirubinemia.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency are more likely to develop hyperbilirubinemia.  Monitoring liver function is recommended and discontinuation of the drug may be necessary.', '2', 'May DG, Arns PA, Richards WO, et al. "The disposition of dapsone in cirrhosis." Clin Pharmacol Ther 51 (1992):  689-700|Fleming CM, Branch RA, Wilkinson GR, Guengerich FP "Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4." Mol Pharmacol 41 (1992):  975-80|Mills J, Leoung G, Ileana M, Hopewell PC, Hughes WT, Wofsy C "Dapsone treatment of pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome." Antimicrob Agents Chemother 32 (1988):  1057-60|"Product Information. Dapsone (dapsone)." Jacobus Pharmaceutical Company  (2022):|Beumont MG, Graziani A, Ubel PA, Macgregor RR "Safety of dapsone as pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole." Am J Med 100 (1996):  611-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42294, 5227, 'Dapsone', 'Liver Diseases', 'The use of dapsone has been associated with the development of hyperbilirubinemia.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency are more likely to develop hyperbilirubinemia.  Monitoring liver function is recommended and discontinuation of the drug may be necessary.', '2', 'May DG, Arns PA, Richards WO, et al. "The disposition of dapsone in cirrhosis." Clin Pharmacol Ther 51 (1992):  689-700|Fleming CM, Branch RA, Wilkinson GR, Guengerich FP "Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4." Mol Pharmacol 41 (1992):  975-80|Mills J, Leoung G, Ileana M, Hopewell PC, Hughes WT, Wofsy C "Dapsone treatment of pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome." Antimicrob Agents Chemother 32 (1988):  1057-60|"Product Information. Dapsone (dapsone)." Jacobus Pharmaceutical Company  (2022):|Beumont MG, Graziani A, Ubel PA, Macgregor RR "Safety of dapsone as pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole." Am J Med 100 (1996):  611-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42295, 12978, 'Dapsone', 'Liver Diseases', 'The use of dapsone has been associated with the development of hyperbilirubinemia.  Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency are more likely to develop hyperbilirubinemia.  Monitoring liver function is recommended and discontinuation of the drug may be necessary.', '2', 'May DG, Arns PA, Richards WO, et al. "The disposition of dapsone in cirrhosis." Clin Pharmacol Ther 51 (1992):  689-700|Fleming CM, Branch RA, Wilkinson GR, Guengerich FP "Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4." Mol Pharmacol 41 (1992):  975-80|Mills J, Leoung G, Ileana M, Hopewell PC, Hughes WT, Wofsy C "Dapsone treatment of pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome." Antimicrob Agents Chemother 32 (1988):  1057-60|"Product Information. Dapsone (dapsone)." Jacobus Pharmaceutical Company  (2022):|Beumont MG, Graziani A, Ubel PA, Macgregor RR "Safety of dapsone as pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole." Am J Med 100 (1996):  611-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42296, 3296, 'Danazol', 'Metrorrhagia', 'The use of danazol is contraindicated in patients with undiagnosed, abnormal genital bleeding.  Patients should be evaluated to ensure that neoplastic lesions are not present.  Alterations of menstruation including irregular cycles, amenorrhea, breakthrough bleeding, and spotting have occurred during danazol therapy.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42297, 3297, 'Danazol', 'Metrorrhagia', 'The use of danazol is contraindicated in patients with undiagnosed, abnormal genital bleeding.  Patients should be evaluated to ensure that neoplastic lesions are not present.  Alterations of menstruation including irregular cycles, amenorrhea, breakthrough bleeding, and spotting have occurred during danazol therapy.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42298, 3315, 'Danazol', 'Metrorrhagia', 'The use of danazol is contraindicated in patients with undiagnosed, abnormal genital bleeding.  Patients should be evaluated to ensure that neoplastic lesions are not present.  Alterations of menstruation including irregular cycles, amenorrhea, breakthrough bleeding, and spotting have occurred during danazol therapy.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42299, 17094, 'Danazol', 'Metrorrhagia', 'The use of danazol is contraindicated in patients with undiagnosed, abnormal genital bleeding.  Patients should be evaluated to ensure that neoplastic lesions are not present.  Alterations of menstruation including irregular cycles, amenorrhea, breakthrough bleeding, and spotting have occurred during danazol therapy.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42300, 17137, 'Danazol', 'Metrorrhagia', 'The use of danazol is contraindicated in patients with undiagnosed, abnormal genital bleeding.  Patients should be evaluated to ensure that neoplastic lesions are not present.  Alterations of menstruation including irregular cycles, amenorrhea, breakthrough bleeding, and spotting have occurred during danazol therapy.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42301, 3296, 'Danazol', 'Prostatic Neoplasms', 'The use of danazol is contraindicated in patients with androgen- dependent tumors.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42302, 3297, 'Danazol', 'Prostatic Neoplasms', 'The use of danazol is contraindicated in patients with androgen- dependent tumors.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42303, 3315, 'Danazol', 'Prostatic Neoplasms', 'The use of danazol is contraindicated in patients with androgen- dependent tumors.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42304, 17094, 'Danazol', 'Prostatic Neoplasms', 'The use of danazol is contraindicated in patients with androgen- dependent tumors.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42305, 17137, 'Danazol', 'Prostatic Neoplasms', 'The use of danazol is contraindicated in patients with androgen- dependent tumors.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42306, 3296, 'Danazol', 'Liver Diseases', 'The use of danazol is contraindicated in patients with severe hepatic impairment.  Danazol is metabolized by the liver to inactive forms.  Metabolic and therapeutic activity of danazol may be altered in patients with severe hepatic dysfunction.  Elevated serum transaminase levels, peliosis hepatis and benign hepatic adenoma have occurred during chronic administration of danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to hepatic dysfunction.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42307, 3297, 'Danazol', 'Liver Diseases', 'The use of danazol is contraindicated in patients with severe hepatic impairment.  Danazol is metabolized by the liver to inactive forms.  Metabolic and therapeutic activity of danazol may be altered in patients with severe hepatic dysfunction.  Elevated serum transaminase levels, peliosis hepatis and benign hepatic adenoma have occurred during chronic administration of danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to hepatic dysfunction.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42308, 3315, 'Danazol', 'Liver Diseases', 'The use of danazol is contraindicated in patients with severe hepatic impairment.  Danazol is metabolized by the liver to inactive forms.  Metabolic and therapeutic activity of danazol may be altered in patients with severe hepatic dysfunction.  Elevated serum transaminase levels, peliosis hepatis and benign hepatic adenoma have occurred during chronic administration of danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to hepatic dysfunction.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42309, 17094, 'Danazol', 'Liver Diseases', 'The use of danazol is contraindicated in patients with severe hepatic impairment.  Danazol is metabolized by the liver to inactive forms.  Metabolic and therapeutic activity of danazol may be altered in patients with severe hepatic dysfunction.  Elevated serum transaminase levels, peliosis hepatis and benign hepatic adenoma have occurred during chronic administration of danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to hepatic dysfunction.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42310, 17137, 'Danazol', 'Liver Diseases', 'The use of danazol is contraindicated in patients with severe hepatic impairment.  Danazol is metabolized by the liver to inactive forms.  Metabolic and therapeutic activity of danazol may be altered in patients with severe hepatic dysfunction.  Elevated serum transaminase levels, peliosis hepatis and benign hepatic adenoma have occurred during chronic administration of danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to hepatic dysfunction.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42311, 3296, 'Danazol', 'Heart Failure', 'Danazol is contraindicated in patients with marked impaired cardiac function.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42312, 3297, 'Danazol', 'Heart Failure', 'Danazol is contraindicated in patients with marked impaired cardiac function.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42313, 3315, 'Danazol', 'Heart Failure', 'Danazol is contraindicated in patients with marked impaired cardiac function.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42314, 17094, 'Danazol', 'Heart Failure', 'Danazol is contraindicated in patients with marked impaired cardiac function.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42315, 17137, 'Danazol', 'Heart Failure', 'Danazol is contraindicated in patients with marked impaired cardiac function.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42316, 3296, 'Danazol', 'Intracranial Hypertension', 'Intracranial hypertension (pseudotumor cerebri) has occurred in patients receiving danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to cerebral  or papilledema and/or intracranial hypertension.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42317, 3297, 'Danazol', 'Intracranial Hypertension', 'Intracranial hypertension (pseudotumor cerebri) has occurred in patients receiving danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to cerebral  or papilledema and/or intracranial hypertension.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42318, 3315, 'Danazol', 'Intracranial Hypertension', 'Intracranial hypertension (pseudotumor cerebri) has occurred in patients receiving danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to cerebral  or papilledema and/or intracranial hypertension.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42319, 17094, 'Danazol', 'Intracranial Hypertension', 'Intracranial hypertension (pseudotumor cerebri) has occurred in patients receiving danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to cerebral  or papilledema and/or intracranial hypertension.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42320, 17137, 'Danazol', 'Intracranial Hypertension', 'Intracranial hypertension (pseudotumor cerebri) has occurred in patients receiving danazol.  Therapy with danazol should be administered cautiously in patients with or predisposed to cerebral  or papilledema and/or intracranial hypertension.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42321, 3296, 'Danazol', 'Porphyrias', 'The use of danazol is contraindicated in patients with porphyria.  Danazol can induce production of delta- aminolevulinic acid (ALA) synthetase activity resulting in porphyrin metabolism.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42322, 3297, 'Danazol', 'Porphyrias', 'The use of danazol is contraindicated in patients with porphyria.  Danazol can induce production of delta- aminolevulinic acid (ALA) synthetase activity resulting in porphyrin metabolism.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42323, 3315, 'Danazol', 'Porphyrias', 'The use of danazol is contraindicated in patients with porphyria.  Danazol can induce production of delta- aminolevulinic acid (ALA) synthetase activity resulting in porphyrin metabolism.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42324, 17094, 'Danazol', 'Porphyrias', 'The use of danazol is contraindicated in patients with porphyria.  Danazol can induce production of delta- aminolevulinic acid (ALA) synthetase activity resulting in porphyrin metabolism.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42325, 17137, 'Danazol', 'Porphyrias', 'The use of danazol is contraindicated in patients with porphyria.  Danazol can induce production of delta- aminolevulinic acid (ALA) synthetase activity resulting in porphyrin metabolism.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42326, 3296, 'Danazol', 'Thromboembolism', 'Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events.  Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy.  Hematuria, menstrual spotting and thrombocytopenia have also occurred.  Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42327, 3297, 'Danazol', 'Thromboembolism', 'Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events.  Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy.  Hematuria, menstrual spotting and thrombocytopenia have also occurred.  Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42328, 3315, 'Danazol', 'Thromboembolism', 'Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events.  Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy.  Hematuria, menstrual spotting and thrombocytopenia have also occurred.  Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42329, 17094, 'Danazol', 'Thromboembolism', 'Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events.  Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy.  Hematuria, menstrual spotting and thrombocytopenia have also occurred.  Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42330, 17137, 'Danazol', 'Thromboembolism', 'Danazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events.  Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy.  Hematuria, menstrual spotting and thrombocytopenia have also occurred.  Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42331, 3296, 'Danazol', 'Kidney Failure, Chronic', 'Danazol possess androgenic activity that can result in salt and water retention.  Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction.  It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension.  These patients will require careful observation.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42332, 3297, 'Danazol', 'Kidney Failure, Chronic', 'Danazol possess androgenic activity that can result in salt and water retention.  Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction.  It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension.  These patients will require careful observation.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42333, 3315, 'Danazol', 'Kidney Failure, Chronic', 'Danazol possess androgenic activity that can result in salt and water retention.  Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction.  It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension.  These patients will require careful observation.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42334, 17094, 'Danazol', 'Kidney Failure, Chronic', 'Danazol possess androgenic activity that can result in salt and water retention.  Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction.  It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension.  These patients will require careful observation.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42335, 17137, 'Danazol', 'Kidney Failure, Chronic', 'Danazol possess androgenic activity that can result in salt and water retention.  Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction.  It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension.  These patients will require careful observation.', '3', '"Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42336, 14119, 'Darifenacin', 'Gastrointestinal Diseases', 'Darifenacin is contraindicated in patients with gastric retention.  Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders and conditions such as severe constipation, ulcerative colitis, and myasthenia gravis because of the risk of gastric retention.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42337, 17115, 'Darifenacin', 'Gastrointestinal Diseases', 'Darifenacin is contraindicated in patients with gastric retention.  Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders and conditions such as severe constipation, ulcerative colitis, and myasthenia gravis because of the risk of gastric retention.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42338, 17116, 'Darifenacin', 'Gastrointestinal Diseases', 'Darifenacin is contraindicated in patients with gastric retention.  Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders and conditions such as severe constipation, ulcerative colitis, and myasthenia gravis because of the risk of gastric retention.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42339, 19401, 'Darifenacin', 'Gastrointestinal Diseases', 'Darifenacin is contraindicated in patients with gastric retention.  Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders and conditions such as severe constipation, ulcerative colitis, and myasthenia gravis because of the risk of gastric retention.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42340, 19402, 'Darifenacin', 'Gastrointestinal Diseases', 'Darifenacin is contraindicated in patients with gastric retention.  Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders and conditions such as severe constipation, ulcerative colitis, and myasthenia gravis because of the risk of gastric retention.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42341, 19403, 'Darifenacin', 'Gastrointestinal Diseases', 'Darifenacin is contraindicated in patients with gastric retention.  Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with gastrointestinal obstructive disorders and conditions such as severe constipation, ulcerative colitis, and myasthenia gravis because of the risk of gastric retention.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42342, 14119, 'Darifenacin', 'Glaucoma', 'Darifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  It is recommended to use darifenacin with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42343, 17115, 'Darifenacin', 'Glaucoma', 'Darifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  It is recommended to use darifenacin with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42344, 17116, 'Darifenacin', 'Glaucoma', 'Darifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  It is recommended to use darifenacin with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42345, 19401, 'Darifenacin', 'Glaucoma', 'Darifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  It is recommended to use darifenacin with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42346, 19402, 'Darifenacin', 'Glaucoma', 'Darifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  It is recommended to use darifenacin with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42347, 19403, 'Darifenacin', 'Glaucoma', 'Darifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  It is recommended to use darifenacin with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42348, 14119, 'Darifenacin', 'Urinary Retention', 'Darifenacin is contraindicated in patients with urinary retention.  Darifenacin is a competitive muscarinic receptor antagonist.  It is recommended to use darifenacin with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42349, 17115, 'Darifenacin', 'Urinary Retention', 'Darifenacin is contraindicated in patients with urinary retention.  Darifenacin is a competitive muscarinic receptor antagonist.  It is recommended to use darifenacin with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42350, 17116, 'Darifenacin', 'Urinary Retention', 'Darifenacin is contraindicated in patients with urinary retention.  Darifenacin is a competitive muscarinic receptor antagonist.  It is recommended to use darifenacin with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42351, 19401, 'Darifenacin', 'Urinary Retention', 'Darifenacin is contraindicated in patients with urinary retention.  Darifenacin is a competitive muscarinic receptor antagonist.  It is recommended to use darifenacin with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42352, 19402, 'Darifenacin', 'Urinary Retention', 'Darifenacin is contraindicated in patients with urinary retention.  Darifenacin is a competitive muscarinic receptor antagonist.  It is recommended to use darifenacin with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42353, 19403, 'Darifenacin', 'Urinary Retention', 'Darifenacin is contraindicated in patients with urinary retention.  Darifenacin is a competitive muscarinic receptor antagonist.  It is recommended to use darifenacin with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.', '3', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42354, 14119, 'Darifenacin', 'Central Nervous System Diseases', 'Darifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after the initiation of treatment or if the dose is increased.  It is recommended to reduce the dose or discontinue treatment if patients experience anticholinergic CNS effects.  Care should be exercised when prescribing this agent to patients presenting headache, confusion, hallucinations, or somnolence as these might worsen with the use of darifenacin.', '2', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42355, 17115, 'Darifenacin', 'Central Nervous System Diseases', 'Darifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after the initiation of treatment or if the dose is increased.  It is recommended to reduce the dose or discontinue treatment if patients experience anticholinergic CNS effects.  Care should be exercised when prescribing this agent to patients presenting headache, confusion, hallucinations, or somnolence as these might worsen with the use of darifenacin.', '2', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42356, 17116, 'Darifenacin', 'Central Nervous System Diseases', 'Darifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after the initiation of treatment or if the dose is increased.  It is recommended to reduce the dose or discontinue treatment if patients experience anticholinergic CNS effects.  Care should be exercised when prescribing this agent to patients presenting headache, confusion, hallucinations, or somnolence as these might worsen with the use of darifenacin.', '2', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42357, 19401, 'Darifenacin', 'Central Nervous System Diseases', 'Darifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after the initiation of treatment or if the dose is increased.  It is recommended to reduce the dose or discontinue treatment if patients experience anticholinergic CNS effects.  Care should be exercised when prescribing this agent to patients presenting headache, confusion, hallucinations, or somnolence as these might worsen with the use of darifenacin.', '2', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42358, 19402, 'Darifenacin', 'Central Nervous System Diseases', 'Darifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after the initiation of treatment or if the dose is increased.  It is recommended to reduce the dose or discontinue treatment if patients experience anticholinergic CNS effects.  Care should be exercised when prescribing this agent to patients presenting headache, confusion, hallucinations, or somnolence as these might worsen with the use of darifenacin.', '2', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42359, 19403, 'Darifenacin', 'Central Nervous System Diseases', 'Darifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after the initiation of treatment or if the dose is increased.  It is recommended to reduce the dose or discontinue treatment if patients experience anticholinergic CNS effects.  Care should be exercised when prescribing this agent to patients presenting headache, confusion, hallucinations, or somnolence as these might worsen with the use of darifenacin.', '2', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42360, 14119, 'Darifenacin', 'Liver Diseases', 'Darifenacin is extensively metabolized by the liver following oral dosing.  The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B).  Darifenacin has not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population.  No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).', '2', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42361, 17115, 'Darifenacin', 'Liver Diseases', 'Darifenacin is extensively metabolized by the liver following oral dosing.  The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B).  Darifenacin has not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population.  No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).', '2', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42362, 17116, 'Darifenacin', 'Liver Diseases', 'Darifenacin is extensively metabolized by the liver following oral dosing.  The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B).  Darifenacin has not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population.  No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).', '2', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42363, 19401, 'Darifenacin', 'Liver Diseases', 'Darifenacin is extensively metabolized by the liver following oral dosing.  The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B).  Darifenacin has not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population.  No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).', '2', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42364, 19402, 'Darifenacin', 'Liver Diseases', 'Darifenacin is extensively metabolized by the liver following oral dosing.  The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B).  Darifenacin has not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population.  No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).', '2', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42365, 19403, 'Darifenacin', 'Liver Diseases', 'Darifenacin is extensively metabolized by the liver following oral dosing.  The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B).  Darifenacin has not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population.  No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).', '2', '"Product Information. Darifenacin ER (darifenacin)." Cipla USA Inc.  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42366, 5848, 'Dasatinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42367, 5850, 'Dasatinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42368, 5852, 'Dasatinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42369, 10837, 'Dasatinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42370, 19609, 'Dasatinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42371, 27431, 'Dasatinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42372, 5848, 'Dasatinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42373, 5850, 'Dasatinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42374, 5852, 'Dasatinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42375, 10837, 'Dasatinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42376, 19609, 'Dasatinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42377, 27431, 'Dasatinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42378, 5848, 'Dasatinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42379, 5850, 'Dasatinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42380, 5852, 'Dasatinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42381, 10837, 'Dasatinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42382, 19609, 'Dasatinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42383, 27431, 'Dasatinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', '"Product Information. Gleevec (imatinib)." Novartis Pharmaceuticals  (2022):|"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):|"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):|"Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42384, 5848, 'Dasatinib', 'Hepatic Insufficiency', 'Caution is advised when administering dasatinib to patients with hepatic impairment.  Monitoring is recommended and dose adjustment might be necessary.', '2', '"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42385, 5850, 'Dasatinib', 'Hepatic Insufficiency', 'Caution is advised when administering dasatinib to patients with hepatic impairment.  Monitoring is recommended and dose adjustment might be necessary.', '2', '"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42386, 5852, 'Dasatinib', 'Hepatic Insufficiency', 'Caution is advised when administering dasatinib to patients with hepatic impairment.  Monitoring is recommended and dose adjustment might be necessary.', '2', '"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42387, 10837, 'Dasatinib', 'Hepatic Insufficiency', 'Caution is advised when administering dasatinib to patients with hepatic impairment.  Monitoring is recommended and dose adjustment might be necessary.', '2', '"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42388, 19609, 'Dasatinib', 'Hepatic Insufficiency', 'Caution is advised when administering dasatinib to patients with hepatic impairment.  Monitoring is recommended and dose adjustment might be necessary.', '2', '"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42389, 27431, 'Dasatinib', 'Hepatic Insufficiency', 'Caution is advised when administering dasatinib to patients with hepatic impairment.  Monitoring is recommended and dose adjustment might be necessary.', '2', '"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42390, 5848, 'Dasatinib', 'Pulmonary Arterial Hypertension', 'Dasatinib can increase the risk of developing pulmonary arterial hypertension (PAH) which may occur any time after treatment initiation, including after more than 1 year of treatment.  Manifestations may include dyspnea, fatigue, hypoxia, and fluid retention.  PAH may be reversible with treatment discontinuation.  Caution should be exercised in patients with underlying cardiopulmonary disease.  If PAH develops, treatment should be discontinued.', '2', '"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42391, 5850, 'Dasatinib', 'Pulmonary Arterial Hypertension', 'Dasatinib can increase the risk of developing pulmonary arterial hypertension (PAH) which may occur any time after treatment initiation, including after more than 1 year of treatment.  Manifestations may include dyspnea, fatigue, hypoxia, and fluid retention.  PAH may be reversible with treatment discontinuation.  Caution should be exercised in patients with underlying cardiopulmonary disease.  If PAH develops, treatment should be discontinued.', '2', '"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42392, 5852, 'Dasatinib', 'Pulmonary Arterial Hypertension', 'Dasatinib can increase the risk of developing pulmonary arterial hypertension (PAH) which may occur any time after treatment initiation, including after more than 1 year of treatment.  Manifestations may include dyspnea, fatigue, hypoxia, and fluid retention.  PAH may be reversible with treatment discontinuation.  Caution should be exercised in patients with underlying cardiopulmonary disease.  If PAH develops, treatment should be discontinued.', '2', '"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42393, 10837, 'Dasatinib', 'Pulmonary Arterial Hypertension', 'Dasatinib can increase the risk of developing pulmonary arterial hypertension (PAH) which may occur any time after treatment initiation, including after more than 1 year of treatment.  Manifestations may include dyspnea, fatigue, hypoxia, and fluid retention.  PAH may be reversible with treatment discontinuation.  Caution should be exercised in patients with underlying cardiopulmonary disease.  If PAH develops, treatment should be discontinued.', '2', '"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42394, 19609, 'Dasatinib', 'Pulmonary Arterial Hypertension', 'Dasatinib can increase the risk of developing pulmonary arterial hypertension (PAH) which may occur any time after treatment initiation, including after more than 1 year of treatment.  Manifestations may include dyspnea, fatigue, hypoxia, and fluid retention.  PAH may be reversible with treatment discontinuation.  Caution should be exercised in patients with underlying cardiopulmonary disease.  If PAH develops, treatment should be discontinued.', '2', '"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42395, 27431, 'Dasatinib', 'Pulmonary Arterial Hypertension', 'Dasatinib can increase the risk of developing pulmonary arterial hypertension (PAH) which may occur any time after treatment initiation, including after more than 1 year of treatment.  Manifestations may include dyspnea, fatigue, hypoxia, and fluid retention.  PAH may be reversible with treatment discontinuation.  Caution should be exercised in patients with underlying cardiopulmonary disease.  If PAH develops, treatment should be discontinued.', '2', '"Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb  (2006):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42396, 5848, 'Dasatinib', 'Long QT Syndrome', 'Dasatinib has shown to prolong QT interval in a concentration-dependent manner.  Caution should be exercised specially in patients with congenital long QT syndrome, patients with hypokalemia, hypomagnesemia, or with history of arrhythmias and on antiarrhythmic medication.  Hypokalemia or hypomagnesemia should be corrected before starting treatment.  Patients at risk should be monitored with an EKG before treatment and periodically as clinically indicated.  Dose adjustments might be needed.', '2', '"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42397, 5850, 'Dasatinib', 'Long QT Syndrome', 'Dasatinib has shown to prolong QT interval in a concentration-dependent manner.  Caution should be exercised specially in patients with congenital long QT syndrome, patients with hypokalemia, hypomagnesemia, or with history of arrhythmias and on antiarrhythmic medication.  Hypokalemia or hypomagnesemia should be corrected before starting treatment.  Patients at risk should be monitored with an EKG before treatment and periodically as clinically indicated.  Dose adjustments might be needed.', '2', '"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42398, 5852, 'Dasatinib', 'Long QT Syndrome', 'Dasatinib has shown to prolong QT interval in a concentration-dependent manner.  Caution should be exercised specially in patients with congenital long QT syndrome, patients with hypokalemia, hypomagnesemia, or with history of arrhythmias and on antiarrhythmic medication.  Hypokalemia or hypomagnesemia should be corrected before starting treatment.  Patients at risk should be monitored with an EKG before treatment and periodically as clinically indicated.  Dose adjustments might be needed.', '2', '"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42399, 10837, 'Dasatinib', 'Long QT Syndrome', 'Dasatinib has shown to prolong QT interval in a concentration-dependent manner.  Caution should be exercised specially in patients with congenital long QT syndrome, patients with hypokalemia, hypomagnesemia, or with history of arrhythmias and on antiarrhythmic medication.  Hypokalemia or hypomagnesemia should be corrected before starting treatment.  Patients at risk should be monitored with an EKG before treatment and periodically as clinically indicated.  Dose adjustments might be needed.', '2', '"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42400, 19609, 'Dasatinib', 'Long QT Syndrome', 'Dasatinib has shown to prolong QT interval in a concentration-dependent manner.  Caution should be exercised specially in patients with congenital long QT syndrome, patients with hypokalemia, hypomagnesemia, or with history of arrhythmias and on antiarrhythmic medication.  Hypokalemia or hypomagnesemia should be corrected before starting treatment.  Patients at risk should be monitored with an EKG before treatment and periodically as clinically indicated.  Dose adjustments might be needed.', '2', '"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42401, 27431, 'Dasatinib', 'Long QT Syndrome', 'Dasatinib has shown to prolong QT interval in a concentration-dependent manner.  Caution should be exercised specially in patients with congenital long QT syndrome, patients with hypokalemia, hypomagnesemia, or with history of arrhythmias and on antiarrhythmic medication.  Hypokalemia or hypomagnesemia should be corrected before starting treatment.  Patients at risk should be monitored with an EKG before treatment and periodically as clinically indicated.  Dose adjustments might be needed.', '2', '"Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42402, 9026, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42403, 11966, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42404, 11967, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42405, 12949, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42406, 12950, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42407, 16927, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42408, 20483, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42409, 21719, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42410, 21720, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42411, 23758, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42412, 25506, 'Allopurinol', 'Bone Marrow Failure Disorders', 'Bone marrow suppression has been reported in patients receiving allopurinol; however, most of these patients were receiving concomitant medications with the known potential to cause such an effect.  The suppression has occurred from as early as 6 weeks to as long as 6 years after the initiation of allopurinol therapy.  Therapy with allopurinol should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42413, 9026, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', 'Landgrebe AR, Nyhan WL, Coleman M "Urinary-tract stones resulting from the excretion of oxypurinol." N Engl J Med 292 (1975):  626-7|Stote RM, Smith LH, Dubb JW, Moyer TP, Alexander F, Roth JL "Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy." Ann Intern Med 92 (1980):  384-5|McInnes GT, Lawson DH, Jick H "Acute adverse reactions attributed to allopurinol in hospitalized patients." Ann Rheum Dis 40 (1981):  245-9|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42414, 11966, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', 'Landgrebe AR, Nyhan WL, Coleman M "Urinary-tract stones resulting from the excretion of oxypurinol." N Engl J Med 292 (1975):  626-7|Stote RM, Smith LH, Dubb JW, Moyer TP, Alexander F, Roth JL "Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy." Ann Intern Med 92 (1980):  384-5|McInnes GT, Lawson DH, Jick H "Acute adverse reactions attributed to allopurinol in hospitalized patients." Ann Rheum Dis 40 (1981):  245-9|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42415, 11967, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', 'Landgrebe AR, Nyhan WL, Coleman M "Urinary-tract stones resulting from the excretion of oxypurinol." N Engl J Med 292 (1975):  626-7|Stote RM, Smith LH, Dubb JW, Moyer TP, Alexander F, Roth JL "Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy." Ann Intern Med 92 (1980):  384-5|McInnes GT, Lawson DH, Jick H "Acute adverse reactions attributed to allopurinol in hospitalized patients." Ann Rheum Dis 40 (1981):  245-9|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42416, 12949, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', 'Landgrebe AR, Nyhan WL, Coleman M "Urinary-tract stones resulting from the excretion of oxypurinol." N Engl J Med 292 (1975):  626-7|Stote RM, Smith LH, Dubb JW, Moyer TP, Alexander F, Roth JL "Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy." Ann Intern Med 92 (1980):  384-5|McInnes GT, Lawson DH, Jick H "Acute adverse reactions attributed to allopurinol in hospitalized patients." Ann Rheum Dis 40 (1981):  245-9|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42417, 12950, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', 'Landgrebe AR, Nyhan WL, Coleman M "Urinary-tract stones resulting from the excretion of oxypurinol." N Engl J Med 292 (1975):  626-7|Stote RM, Smith LH, Dubb JW, Moyer TP, Alexander F, Roth JL "Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy." Ann Intern Med 92 (1980):  384-5|McInnes GT, Lawson DH, Jick H "Acute adverse reactions attributed to allopurinol in hospitalized patients." Ann Rheum Dis 40 (1981):  245-9|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42418, 16927, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', 'Landgrebe AR, Nyhan WL, Coleman M "Urinary-tract stones resulting from the excretion of oxypurinol." N Engl J Med 292 (1975):  626-7|Stote RM, Smith LH, Dubb JW, Moyer TP, Alexander F, Roth JL "Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy." Ann Intern Med 92 (1980):  384-5|McInnes GT, Lawson DH, Jick H "Acute adverse reactions attributed to allopurinol in hospitalized patients." Ann Rheum Dis 40 (1981):  245-9|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42419, 20483, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', 'Landgrebe AR, Nyhan WL, Coleman M "Urinary-tract stones resulting from the excretion of oxypurinol." N Engl J Med 292 (1975):  626-7|Stote RM, Smith LH, Dubb JW, Moyer TP, Alexander F, Roth JL "Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy." Ann Intern Med 92 (1980):  384-5|McInnes GT, Lawson DH, Jick H "Acute adverse reactions attributed to allopurinol in hospitalized patients." Ann Rheum Dis 40 (1981):  245-9|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42420, 21719, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', 'Landgrebe AR, Nyhan WL, Coleman M "Urinary-tract stones resulting from the excretion of oxypurinol." N Engl J Med 292 (1975):  626-7|Stote RM, Smith LH, Dubb JW, Moyer TP, Alexander F, Roth JL "Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy." Ann Intern Med 92 (1980):  384-5|McInnes GT, Lawson DH, Jick H "Acute adverse reactions attributed to allopurinol in hospitalized patients." Ann Rheum Dis 40 (1981):  245-9|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42421, 21720, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', 'Landgrebe AR, Nyhan WL, Coleman M "Urinary-tract stones resulting from the excretion of oxypurinol." N Engl J Med 292 (1975):  626-7|Stote RM, Smith LH, Dubb JW, Moyer TP, Alexander F, Roth JL "Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy." Ann Intern Med 92 (1980):  384-5|McInnes GT, Lawson DH, Jick H "Acute adverse reactions attributed to allopurinol in hospitalized patients." Ann Rheum Dis 40 (1981):  245-9|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42422, 23758, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', 'Landgrebe AR, Nyhan WL, Coleman M "Urinary-tract stones resulting from the excretion of oxypurinol." N Engl J Med 292 (1975):  626-7|Stote RM, Smith LH, Dubb JW, Moyer TP, Alexander F, Roth JL "Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy." Ann Intern Med 92 (1980):  384-5|McInnes GT, Lawson DH, Jick H "Acute adverse reactions attributed to allopurinol in hospitalized patients." Ann Rheum Dis 40 (1981):  245-9|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42423, 25506, 'Allopurinol', 'Dehydration', 'Adequate hydration is necessary during therapy with allopurinol to prevent both the formation of xanthine calculi and renal precipitation of urates when concomitant uricosuric agents are given.  Patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid.  In general, fluid intake sufficient to yield a daily urinary output of at least 2 liters is recommended.  Maintenance of a slightly alkaline or neutral urine is also desirable.', '2', 'Landgrebe AR, Nyhan WL, Coleman M "Urinary-tract stones resulting from the excretion of oxypurinol." N Engl J Med 292 (1975):  626-7|Stote RM, Smith LH, Dubb JW, Moyer TP, Alexander F, Roth JL "Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy." Ann Intern Med 92 (1980):  384-5|McInnes GT, Lawson DH, Jick H "Acute adverse reactions attributed to allopurinol in hospitalized patients." Ann Rheum Dis 40 (1981):  245-9|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42424, 9026, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', 'Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG "Allopurinol hepatotoxicity." Ann Intern Med 95 (1981):  588-90|Raper R, Ibels L, Lauer C, Barnes P, Lunzer M "Fulminant hepatic failure due to allopurinol." Aust N Z J Med 14 (1984):  63-5|Ohsawa T, Ohtsubo M "Hepatitis associated with allopurinol." Drug Intell Clin Pharm 19 (1985):  431-3|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42425, 11966, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', 'Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG "Allopurinol hepatotoxicity." Ann Intern Med 95 (1981):  588-90|Raper R, Ibels L, Lauer C, Barnes P, Lunzer M "Fulminant hepatic failure due to allopurinol." Aust N Z J Med 14 (1984):  63-5|Ohsawa T, Ohtsubo M "Hepatitis associated with allopurinol." Drug Intell Clin Pharm 19 (1985):  431-3|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42426, 11967, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', 'Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG "Allopurinol hepatotoxicity." Ann Intern Med 95 (1981):  588-90|Raper R, Ibels L, Lauer C, Barnes P, Lunzer M "Fulminant hepatic failure due to allopurinol." Aust N Z J Med 14 (1984):  63-5|Ohsawa T, Ohtsubo M "Hepatitis associated with allopurinol." Drug Intell Clin Pharm 19 (1985):  431-3|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42427, 12949, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', 'Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG "Allopurinol hepatotoxicity." Ann Intern Med 95 (1981):  588-90|Raper R, Ibels L, Lauer C, Barnes P, Lunzer M "Fulminant hepatic failure due to allopurinol." Aust N Z J Med 14 (1984):  63-5|Ohsawa T, Ohtsubo M "Hepatitis associated with allopurinol." Drug Intell Clin Pharm 19 (1985):  431-3|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42428, 12950, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', 'Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG "Allopurinol hepatotoxicity." Ann Intern Med 95 (1981):  588-90|Raper R, Ibels L, Lauer C, Barnes P, Lunzer M "Fulminant hepatic failure due to allopurinol." Aust N Z J Med 14 (1984):  63-5|Ohsawa T, Ohtsubo M "Hepatitis associated with allopurinol." Drug Intell Clin Pharm 19 (1985):  431-3|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42429, 16927, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', 'Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG "Allopurinol hepatotoxicity." Ann Intern Med 95 (1981):  588-90|Raper R, Ibels L, Lauer C, Barnes P, Lunzer M "Fulminant hepatic failure due to allopurinol." Aust N Z J Med 14 (1984):  63-5|Ohsawa T, Ohtsubo M "Hepatitis associated with allopurinol." Drug Intell Clin Pharm 19 (1985):  431-3|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42430, 20483, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', 'Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG "Allopurinol hepatotoxicity." Ann Intern Med 95 (1981):  588-90|Raper R, Ibels L, Lauer C, Barnes P, Lunzer M "Fulminant hepatic failure due to allopurinol." Aust N Z J Med 14 (1984):  63-5|Ohsawa T, Ohtsubo M "Hepatitis associated with allopurinol." Drug Intell Clin Pharm 19 (1985):  431-3|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42431, 21719, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', 'Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG "Allopurinol hepatotoxicity." Ann Intern Med 95 (1981):  588-90|Raper R, Ibels L, Lauer C, Barnes P, Lunzer M "Fulminant hepatic failure due to allopurinol." Aust N Z J Med 14 (1984):  63-5|Ohsawa T, Ohtsubo M "Hepatitis associated with allopurinol." Drug Intell Clin Pharm 19 (1985):  431-3|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42432, 21720, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', 'Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG "Allopurinol hepatotoxicity." Ann Intern Med 95 (1981):  588-90|Raper R, Ibels L, Lauer C, Barnes P, Lunzer M "Fulminant hepatic failure due to allopurinol." Aust N Z J Med 14 (1984):  63-5|Ohsawa T, Ohtsubo M "Hepatitis associated with allopurinol." Drug Intell Clin Pharm 19 (1985):  431-3|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42433, 23758, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', 'Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG "Allopurinol hepatotoxicity." Ann Intern Med 95 (1981):  588-90|Raper R, Ibels L, Lauer C, Barnes P, Lunzer M "Fulminant hepatic failure due to allopurinol." Aust N Z J Med 14 (1984):  63-5|Ohsawa T, Ohtsubo M "Hepatitis associated with allopurinol." Drug Intell Clin Pharm 19 (1985):  431-3|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42434, 25506, 'Allopurinol', 'Liver Diseases', 'The use of allopurinol has infrequently been associated with asymptomatic elevations of serum transaminase and alkaline phosphatase levels.  Isolated cases of cholestatic jaundice, hepatic necrosis, granulomatous hepatitis, and hepatomegaly have also been reported.  Therapy with allopurinol should be administered cautiously in patients with liver disease.  Periodic monitoring of liver function tests is recommended in these patients during the early stages of therapy.', '2', 'Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG "Allopurinol hepatotoxicity." Ann Intern Med 95 (1981):  588-90|Raper R, Ibels L, Lauer C, Barnes P, Lunzer M "Fulminant hepatic failure due to allopurinol." Aust N Z J Med 14 (1984):  63-5|Ohsawa T, Ohtsubo M "Hepatitis associated with allopurinol." Drug Intell Clin Pharm 19 (1985):  431-3|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42435, 9026, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', 'Hande K, Reed E, Chabner B "Allopurinol kinetics." Clin Pharmacol Ther 23 (1978):  598-605|Hande KR, Noone RM, Stone WJ "Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency." Am J Med 76 (1984):  47-56|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42436, 11966, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', 'Hande K, Reed E, Chabner B "Allopurinol kinetics." Clin Pharmacol Ther 23 (1978):  598-605|Hande KR, Noone RM, Stone WJ "Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency." Am J Med 76 (1984):  47-56|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42437, 11967, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', 'Hande K, Reed E, Chabner B "Allopurinol kinetics." Clin Pharmacol Ther 23 (1978):  598-605|Hande KR, Noone RM, Stone WJ "Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency." Am J Med 76 (1984):  47-56|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42438, 12949, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', 'Hande K, Reed E, Chabner B "Allopurinol kinetics." Clin Pharmacol Ther 23 (1978):  598-605|Hande KR, Noone RM, Stone WJ "Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency." Am J Med 76 (1984):  47-56|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42439, 12950, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', 'Hande K, Reed E, Chabner B "Allopurinol kinetics." Clin Pharmacol Ther 23 (1978):  598-605|Hande KR, Noone RM, Stone WJ "Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency." Am J Med 76 (1984):  47-56|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42440, 16927, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', 'Hande K, Reed E, Chabner B "Allopurinol kinetics." Clin Pharmacol Ther 23 (1978):  598-605|Hande KR, Noone RM, Stone WJ "Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency." Am J Med 76 (1984):  47-56|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42441, 20483, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', 'Hande K, Reed E, Chabner B "Allopurinol kinetics." Clin Pharmacol Ther 23 (1978):  598-605|Hande KR, Noone RM, Stone WJ "Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency." Am J Med 76 (1984):  47-56|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42442, 21719, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', 'Hande K, Reed E, Chabner B "Allopurinol kinetics." Clin Pharmacol Ther 23 (1978):  598-605|Hande KR, Noone RM, Stone WJ "Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency." Am J Med 76 (1984):  47-56|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42443, 21720, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', 'Hande K, Reed E, Chabner B "Allopurinol kinetics." Clin Pharmacol Ther 23 (1978):  598-605|Hande KR, Noone RM, Stone WJ "Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency." Am J Med 76 (1984):  47-56|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42444, 23758, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', 'Hande K, Reed E, Chabner B "Allopurinol kinetics." Clin Pharmacol Ther 23 (1978):  598-605|Hande KR, Noone RM, Stone WJ "Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency." Am J Med 76 (1984):  47-56|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42445, 25506, 'Allopurinol', 'Kidney Diseases', 'Patients with decreased renal function require lower dosages of allopurinol than normal to control serum urate levels.  Therapy should be initiated at reduced dosages with smaller incremental changes in such patients.  Additionally, individuals with preexisting renal disease or poor urate clearance have demonstrated a rise in BUN during therapy with allopurinol.  Renal failure has also been observed among some with hyperuricemia secondary to neoplastic diseases.  Renal function should be monitored during the initial stages of therapy, and the dosage reduced or the drug withdrawn if necessary.', '2', 'Hande K, Reed E, Chabner B "Allopurinol kinetics." Clin Pharmacol Ther 23 (1978):  598-605|Hande KR, Noone RM, Stone WJ "Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency." Am J Med 76 (1984):  47-56|"Product Information. Zyloprim (allopurinol)." Glaxo Wellcome  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42446, 17122, 'Daunorubicin', 'Heart Failure', 'Daunorubicin can cause myocardial toxicity leading to congestive heart failure.  Patients with preexisting heart disease or prior anthracycline therapy are at increased risk of congestive heart failure.  The benefit-to-risk ratio of daunorubicin therapy in such patients should be weighed before starting treatment.  The incidence of drug-induced congestive heart failure in adults is increased when the total cumulative dose of daunorubicin exceeds 550/mg/m2.  An electrocardiogram and/or determination of systolic ejection fraction prior to each course of therapy is recommended.', '3', 'Mhatre R, Herman E, Huidobro A, Waravdekar V "The possible relationship between metabolism and cardiac toxicity of duanomycin and related compounds." J Pharmacol Exp Ther 178 (1971):  216-22|Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM "Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases." Am J Med 62 (1977):  200-8|Harrison DT, Sanders LA "Letter: Pericarditis in a case of early daunorubicin cardiomyopathy." Ann Intern Med 85 (1976):  339-41|Al-Ismail SA, Parry DH, Whittaker JA "Anthracycline cardiotoxicity and acute myelogenous leukaemia." Br Med J 1 (1977):  815|Buja LM, Ferrans VJ, Mayer RJ, Roberts WC, Henderson ES "Cardiac ultrastructural changes induced by daunorubicin therapy." Cancer 32 (1973):  771-88|Malhotra OP, Talwar KK, Chopra P, Kumar R "Erythroleukaemia and daunorubicin-induced cardiotoxicity in a young boy." Br J Clin Pract 44 (1990):  633-4|Von Hoff DD, Layard M "Risk factors for development of daunorubicin cardiotoxicity." Cancer Treat Rep 65 Suppl 4 (1981):  19-23|Ferrans VJ "Overview of cardiac pathology in relation to anthracycline cardiotoxicity." Cancer Treat Rep 62 (1978):  955-61|Ainger LE, Bushore J, Johnson WW, Ito J "Daunomycin: a cardiotoxic agent." J Natl Med Assoc 63 (1971):  261-7|Kajihara H, Yokozaki H, Yamahara M, Kadomoto Y, Tahara E "Anthracycline induced myocardial damage. An analysis of 16 autopsy cases." Pathol Res Pract 181 (1986):  434-41|"Daunorubicin and the heart." Br Med J 4 (1974):  431-2|"Product Information. Daunoxome (daunorubicin liposomal)." Nexstar Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42447, 17123, 'Daunorubicin', 'Heart Failure', 'Daunorubicin can cause myocardial toxicity leading to congestive heart failure.  Patients with preexisting heart disease or prior anthracycline therapy are at increased risk of congestive heart failure.  The benefit-to-risk ratio of daunorubicin therapy in such patients should be weighed before starting treatment.  The incidence of drug-induced congestive heart failure in adults is increased when the total cumulative dose of daunorubicin exceeds 550/mg/m2.  An electrocardiogram and/or determination of systolic ejection fraction prior to each course of therapy is recommended.', '3', 'Mhatre R, Herman E, Huidobro A, Waravdekar V "The possible relationship between metabolism and cardiac toxicity of duanomycin and related compounds." J Pharmacol Exp Ther 178 (1971):  216-22|Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM "Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases." Am J Med 62 (1977):  200-8|Harrison DT, Sanders LA "Letter: Pericarditis in a case of early daunorubicin cardiomyopathy." Ann Intern Med 85 (1976):  339-41|Al-Ismail SA, Parry DH, Whittaker JA "Anthracycline cardiotoxicity and acute myelogenous leukaemia." Br Med J 1 (1977):  815|Buja LM, Ferrans VJ, Mayer RJ, Roberts WC, Henderson ES "Cardiac ultrastructural changes induced by daunorubicin therapy." Cancer 32 (1973):  771-88|Malhotra OP, Talwar KK, Chopra P, Kumar R "Erythroleukaemia and daunorubicin-induced cardiotoxicity in a young boy." Br J Clin Pract 44 (1990):  633-4|Von Hoff DD, Layard M "Risk factors for development of daunorubicin cardiotoxicity." Cancer Treat Rep 65 Suppl 4 (1981):  19-23|Ferrans VJ "Overview of cardiac pathology in relation to anthracycline cardiotoxicity." Cancer Treat Rep 62 (1978):  955-61|Ainger LE, Bushore J, Johnson WW, Ito J "Daunomycin: a cardiotoxic agent." J Natl Med Assoc 63 (1971):  261-7|Kajihara H, Yokozaki H, Yamahara M, Kadomoto Y, Tahara E "Anthracycline induced myocardial damage. An analysis of 16 autopsy cases." Pathol Res Pract 181 (1986):  434-41|"Daunorubicin and the heart." Br Med J 4 (1974):  431-2|"Product Information. Daunoxome (daunorubicin liposomal)." Nexstar Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42448, 17122, 'Daunorubicin', 'Infections', 'Daunorubicin can induce severe myelosuppression at therapeutic doses.  The use of daunorubicin may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with daunorubicin.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daunoxome (daunorubicin liposomal)." Nexstar Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42449, 17123, 'Daunorubicin', 'Infections', 'Daunorubicin can induce severe myelosuppression at therapeutic doses.  The use of daunorubicin may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with daunorubicin.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daunoxome (daunorubicin liposomal)." Nexstar Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42450, 17122, 'Daunorubicin', 'Bone Marrow Failure Disorders', 'Daunorubicin hydrochloride is a potent bone marrow suppressant.  Suppression will occur in all patients given a therapeutic dose of the drug.  Therapy with daunorubicin hydrochloride should not be started in patients with preexisting drug-induced bone marrow suppression unless the benefit from such treatment warrants the risk.  Persistent, severe myelosuppression may result in superinfection or hemorrhage.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.', '3', '"Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daunoxome (daunorubicin liposomal)." Nexstar Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42451, 17123, 'Daunorubicin', 'Bone Marrow Failure Disorders', 'Daunorubicin hydrochloride is a potent bone marrow suppressant.  Suppression will occur in all patients given a therapeutic dose of the drug.  Therapy with daunorubicin hydrochloride should not be started in patients with preexisting drug-induced bone marrow suppression unless the benefit from such treatment warrants the risk.  Persistent, severe myelosuppression may result in superinfection or hemorrhage.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.', '3', '"Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daunoxome (daunorubicin liposomal)." Nexstar Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42452, 17122, 'Daunorubicin', 'Liver Diseases', 'Daunorubicin is extensively metabolized to a biologically active form within normal erythrocytes and leukocytes.  Further metabolism via reduction and conjugation has been demonstrated.  Approximately 40% of daunorubicin is eliminated in an active form by biliary excretion.  Patients with hepatic impairment may be at increased risk for toxicity. Therapy with daunorubicin should be administered cautiously and the dosage reduced in patients with compromised hepatic function.  Clinical evaluation of liver function prior to each course of treatment with daunorubicin is recommended.', '2', '"Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42453, 17123, 'Daunorubicin', 'Liver Diseases', 'Daunorubicin is extensively metabolized to a biologically active form within normal erythrocytes and leukocytes.  Further metabolism via reduction and conjugation has been demonstrated.  Approximately 40% of daunorubicin is eliminated in an active form by biliary excretion.  Patients with hepatic impairment may be at increased risk for toxicity. Therapy with daunorubicin should be administered cautiously and the dosage reduced in patients with compromised hepatic function.  Clinical evaluation of liver function prior to each course of treatment with daunorubicin is recommended.', '2', '"Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42454, 17122, 'Daunorubicin', 'Kidney Diseases', 'Approximately 25% of daunorubicin is eliminated in an active form in the urine.  Patient with renal impairment are at risk of greater toxicity noted at the recommended dose of daunorubicin.  Therapy with daunorubicin should be administered cautiously and at a reduced dosage in patients with significantly compromised renal function.  Clinical evaluation of renal function prior to each course of treatment is recommended.', '2', 'Burke JF Jr, Laucius JF, Brodovsky HS, Soriano RZ "Doxorubicin hydrochloride-associated renal failure." Arch Intern Med 137 (1977):  385-8|Thomson M, de Arriba G, Ordi J, Oliva H, Hernando L "Acute myelogenous leukemia treated with daunomycin associated with nephrotic syndrome." Nephron 51 (1989):  261-4|Morino N, Nojima Y, Mimura T, Hamasai K, Nakamoto T, Hirai H, Arai M, Matsuya S, Yazaki Y "Nephrotic syndrome developed in a patient with acute promyelocytic leukemia treated with daunomycin." Nephron 70 (1995):  374-5|"Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42455, 17123, 'Daunorubicin', 'Kidney Diseases', 'Approximately 25% of daunorubicin is eliminated in an active form in the urine.  Patient with renal impairment are at risk of greater toxicity noted at the recommended dose of daunorubicin.  Therapy with daunorubicin should be administered cautiously and at a reduced dosage in patients with significantly compromised renal function.  Clinical evaluation of renal function prior to each course of treatment is recommended.', '2', 'Burke JF Jr, Laucius JF, Brodovsky HS, Soriano RZ "Doxorubicin hydrochloride-associated renal failure." Arch Intern Med 137 (1977):  385-8|Thomson M, de Arriba G, Ordi J, Oliva H, Hernando L "Acute myelogenous leukemia treated with daunomycin associated with nephrotic syndrome." Nephron 51 (1989):  261-4|Morino N, Nojima Y, Mimura T, Hamasai K, Nakamoto T, Hirai H, Arai M, Matsuya S, Yazaki Y "Nephrotic syndrome developed in a patient with acute promyelocytic leukemia treated with daunomycin." Nephron 70 (1995):  374-5|"Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42456, 17120, 'Daratumumab', 'Pancytopenia', 'The use of daratumumab may increase neutropenia and thrombocytopenia induced by background therapy.  It is recommended to monitor complete blood cell counts periodically during treatment according to manufacturer''s prescribing information for background therapies.  Dose delay may be required to allow recovery of neutrophils and platelets and supportive care should be considered.', '2', '"Product Information. Darzalex (daratumumab)." Janssen Biotech, Inc.  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42457, 17121, 'Daratumumab', 'Pancytopenia', 'The use of daratumumab may increase neutropenia and thrombocytopenia induced by background therapy.  It is recommended to monitor complete blood cell counts periodically during treatment according to manufacturer''s prescribing information for background therapies.  Dose delay may be required to allow recovery of neutrophils and platelets and supportive care should be considered.', '2', '"Product Information. Darzalex (daratumumab)." Janssen Biotech, Inc.  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42458, 32709, 'Daratumumab', 'Pancytopenia', 'The use of daratumumab may increase neutropenia and thrombocytopenia induced by background therapy.  It is recommended to monitor complete blood cell counts periodically during treatment according to manufacturer''s prescribing information for background therapies.  Dose delay may be required to allow recovery of neutrophils and platelets and supportive care should be considered.', '2', '"Product Information. Darzalex (daratumumab)." Janssen Biotech, Inc.  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42459, 17120, 'Daratumumab', 'Cardiovascular Diseases', 'The use of daratumumab can cause severe infusion reactions, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema.  Caution should be taken in patients with a history of chronic obstructive pulmonary disease as they may require additional post-infusion medications to manage respiratory complications as appropriate.', '2', '"Product Information. Darzalex (daratumumab)." Janssen Biotech, Inc.  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42460, 17121, 'Daratumumab', 'Cardiovascular Diseases', 'The use of daratumumab can cause severe infusion reactions, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema.  Caution should be taken in patients with a history of chronic obstructive pulmonary disease as they may require additional post-infusion medications to manage respiratory complications as appropriate.', '2', '"Product Information. Darzalex (daratumumab)." Janssen Biotech, Inc.  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42461, 32709, 'Daratumumab', 'Cardiovascular Diseases', 'The use of daratumumab can cause severe infusion reactions, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema.  Caution should be taken in patients with a history of chronic obstructive pulmonary disease as they may require additional post-infusion medications to manage respiratory complications as appropriate.', '2', '"Product Information. Darzalex (daratumumab)." Janssen Biotech, Inc.  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42462, 3511, 'Deferoxamine', 'Kidney Diseases', 'The use of deferoxamine is contraindicated in patients with severe renal impairment or anuria.  Deferoxamine chelates iron and the complexes are primarily eliminated by the kidney.', '3', '"Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42463, 17389, 'Deferoxamine', 'Kidney Diseases', 'The use of deferoxamine is contraindicated in patients with severe renal impairment or anuria.  Deferoxamine chelates iron and the complexes are primarily eliminated by the kidney.', '3', '"Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42464, 3511, 'Deferoxamine', 'Auditory Diseases, Central', 'Neurotoxicity-related auditory abnormalities such as tinnitus and hearing loss including deafness have occurred after prolonged therapy or large doses of deferoxamine, or in patients with low ferritin levels.  Therapy with deferoxamine should be administered cautiously in patients with hearing impairment.  Hearing toxicity is usually reversible if detected early and deferoxamine discontinued.', '2', '"Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42465, 17389, 'Deferoxamine', 'Auditory Diseases, Central', 'Neurotoxicity-related auditory abnormalities such as tinnitus and hearing loss including deafness have occurred after prolonged therapy or large doses of deferoxamine, or in patients with low ferritin levels.  Therapy with deferoxamine should be administered cautiously in patients with hearing impairment.  Hearing toxicity is usually reversible if detected early and deferoxamine discontinued.', '2', '"Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42466, 3511, 'Deferoxamine', 'Hepatic Insufficiency', 'No studies of deferoxamine have been performed in patients with hepatic impairment.  Caution is advised.', '2', '"Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42467, 17389, 'Deferoxamine', 'Hepatic Insufficiency', 'No studies of deferoxamine have been performed in patients with hepatic impairment.  Caution is advised.', '2', '"Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42468, 3511, 'Deferoxamine', 'Toxic Optic Neuropathy', 'Deferoxamine may cause blurred vision, cataracts, decreased visual acuity, and impaired color, peripheral, and night vision.  Ocular toxicities have occurred after prolonged therapy, large doses, and in patients with decreased ferritin levels.  Therapy with deferoxamine should be administered cautiously in patients with or predisposed to visual defects.  Periodic examination of visual acuity is recommended in patients receiving long term deferoxamine therapy.  Ocular dysfunction is usually reversible if detected early and deferoxamine is withdrawn promptly.', '2', '"Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42469, 17389, 'Deferoxamine', 'Toxic Optic Neuropathy', 'Deferoxamine may cause blurred vision, cataracts, decreased visual acuity, and impaired color, peripheral, and night vision.  Ocular toxicities have occurred after prolonged therapy, large doses, and in patients with decreased ferritin levels.  Therapy with deferoxamine should be administered cautiously in patients with or predisposed to visual defects.  Periodic examination of visual acuity is recommended in patients receiving long term deferoxamine therapy.  Ocular dysfunction is usually reversible if detected early and deferoxamine is withdrawn promptly.', '2', '"Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42470, 3511, 'Deferoxamine', 'Respiratory Distress Syndrome', 'Acute respiratory distress syndrome has been described in patients with acute iron intoxication or thalassemia following treatment with excessively high intravenous doses of deferoxamine.  Caution is recommended when using deferoxamine in these patients.', '2', '"Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42471, 17389, 'Deferoxamine', 'Respiratory Distress Syndrome', 'Acute respiratory distress syndrome has been described in patients with acute iron intoxication or thalassemia following treatment with excessively high intravenous doses of deferoxamine.  Caution is recommended when using deferoxamine in these patients.', '2', '"Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42472, 17053, 'Decitabine', 'Liver Failure', 'There are no data on the use of decitabine in patients with hepatic dysfunction.  Decitabine should be used with caution in these patients.', '2', '"Product Information. Decitabine (decitabine)." Accord Healthcare Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42473, 17053, 'Decitabine', 'Hematologic Diseases', 'Treatment with decitabine is associated with neutropenia and thrombocytopenia.  It is recommended to consider the need for early institution of growth factors and/or antimicrobial agents for the prevention or treatment of infections in patients with myelodysplastic syndromes (MDS).  Complete blood and platelet counts should be performed as needed to monitor response and toxicity, but at a minimum, before each dosing cycle.  After administration of the recommended dosage for the first cycle, treatment for subsequent cycles should be adjusted according to manufacturer recommendations.  Myelosuppression and worsening neutropenia may occur more frequently in the first or second treatment cycles and may not necessarily indicate progression of underlying MDS.  Closely monitor patients at risk for hematological toxicities.', '2', '"Product Information. Decitabine (decitabine)." Accord Healthcare Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42474, 17053, 'Decitabine', 'Kidney Diseases', 'There are no data on the use of decitabine in patients with renal dysfunction.  Decitabine should be used with caution in these patients.', '2', '"Product Information. Decitabine (decitabine)." Accord Healthcare Inc  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42475, 14130, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42476, 17181, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42477, 17182, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42478, 17183, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42479, 21118, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42480, 21119, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42481, 21120, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42482, 25727, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42483, 25728, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42484, 25729, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42485, 26273, 'Deferasirox', 'Bone Marrow Failure Disorders', 'The use of deferasirox is contraindicated in patients with platelet counts below 50 x 109/L.  Cytopenias, worsening anemia, and thrombocytopenia, including fatal events, have been reported in patients treated with deferasirox.  Preexisting hematologic disorders may increase this risk.  It is recommended to monitor blood counts in all patients and to interrupt treatment in patients who develop cytopenias until the cause of the cytopenia has been determined.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42486, 14130, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42487, 17181, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42488, 17182, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42489, 17183, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42490, 21118, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42491, 21119, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42492, 21120, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42493, 25727, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42494, 25728, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42495, 25729, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42496, 26273, 'Deferasirox', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme have occurred in patients treated with deferasirox.  The risk of other skin reactions cannot be excluded.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with deferasirox.  Monitor patients for the development of these severe cutaneous reactions, discontinue deferasirox if clinically appropriate and do not reintroduce therapy.  For severe cases of rash, interrupt treatment and consider reintroducing therapy after resolution of the rash at a lower dose with dose escalation as appropriate.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42497, 14130, 'Deferasirox', 'Hepatic Insufficiency', 'The use of deferasirox should be avoided in patients with severe hepatic impairment.  The starting dose of deferasirox should be reduced by 50% in patients with moderate hepatic impairment.  It is recommended to measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly or more frequently as clinically appropriate.  Closely monitor patients with mild or moderate hepatic impairment for efficacy and adverse reactions that may require dose titration.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42498, 17181, 'Deferasirox', 'Hepatic Insufficiency', 'The use of deferasirox should be avoided in patients with severe hepatic impairment.  The starting dose of deferasirox should be reduced by 50% in patients with moderate hepatic impairment.  It is recommended to measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly or more frequently as clinically appropriate.  Closely monitor patients with mild or moderate hepatic impairment for efficacy and adverse reactions that may require dose titration.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42499, 17182, 'Deferasirox', 'Hepatic Insufficiency', 'The use of deferasirox should be avoided in patients with severe hepatic impairment.  The starting dose of deferasirox should be reduced by 50% in patients with moderate hepatic impairment.  It is recommended to measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly or more frequently as clinically appropriate.  Closely monitor patients with mild or moderate hepatic impairment for efficacy and adverse reactions that may require dose titration.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42500, 17183, 'Deferasirox', 'Hepatic Insufficiency', 'The use of deferasirox should be avoided in patients with severe hepatic impairment.  The starting dose of deferasirox should be reduced by 50% in patients with moderate hepatic impairment.  It is recommended to measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly or more frequently as clinically appropriate.  Closely monitor patients with mild or moderate hepatic impairment for efficacy and adverse reactions that may require dose titration.', '3', '"Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals  (2005):', 'DDInter', 0);
